<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005265" GROUP_ID="LIVER" ID="399103061314540363" MERGED_FROM="" MODIFIED="2010-11-10 23:16:09 +0100" MODIFIED_BY="Dimitrinka Nikolova" REVIEW_NO="01" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.3">
<COVER_SHEET MODIFIED="2010-11-10 23:12:03 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE>Antibiotic prophylaxis for patients undergoing elective laparoscopic cholecystectomy</TITLE>
<CONTACT>
<PERSON ID="5C91449C82E26AA2010EE5B896E322C6" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Alvaro</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Sanabria</LAST_NAME>
<SUFFIX/>
<POSITION>MD,MSc, PhD, Director</POSITION>
<EMAIL_1>alvarosanabria@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Surgery</DEPARTMENT>
<ORGANISATION>School of Medicine-Universidad de La Sabana, Fundación Abood Shaio</ORGANISATION>
<ADDRESS_1>Campus Puente del Comun km 21 via Chia</ADDRESS_1>
<ADDRESS_2/>
<CITY>Chia</CITY>
<ZIP/>
<REGION>Cundinamarca</REGION>
<COUNTRY CODE="CO">Colombia</COUNTRY>
<PHONE_1>57 1 8615555 ext. 2526</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2010-11-10 23:12:03 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<PERSON ID="5C91449C82E26AA2010EE5B896E322C6" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Alvaro</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Sanabria</LAST_NAME>
<SUFFIX/>
<POSITION>MD,MSc, PhD, Director</POSITION>
<EMAIL_1>alvarosanabria@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Surgery</DEPARTMENT>
<ORGANISATION>School of Medicine-Universidad de La Sabana, Fundación Abood Shaio</ORGANISATION>
<ADDRESS_1>Campus Puente del Comun km 21 via Chia</ADDRESS_1>
<ADDRESS_2/>
<CITY>Chia</CITY>
<ZIP/>
<REGION>Cundinamarca</REGION>
<COUNTRY CODE="CO">Colombia</COUNTRY>
<PHONE_1>57 1 8615555 ext. 2526</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="F10B40A582E26AA20178986B2F62FBCC" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Luis</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Dominguez</LAST_NAME>
<SUFFIX>MD, MSc</SUFFIX>
<POSITION/>
<EMAIL_1>lucardo61@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Surgery</DEPARTMENT>
<ORGANISATION>Hospital Universitario San Ignacio - Pontificia Universidad Javeriana</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Bogota</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CO">Colombia</COUNTRY>
<PHONE_1>(571) 5946161</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="A16DE6F882E26AA2013A09341C1478A2" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Eduardo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Valdivieso</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION>Professor</POSITION>
<EMAIL_1>evaruma@cable.net.co</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Surgery</DEPARTMENT>
<ORGANISATION>School of Medicine-Pontificia Universidad Javeriana</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Bogota</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CO">Colombia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="A16DE7B382E26AA2013A09348C52D78F" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Gabriel</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gomez</LAST_NAME>
<SUFFIX>MD, MPH</SUFFIX>
<POSITION>Titular Professor</POSITION>
<EMAIL_1>ggomez@javeriana.edu.co</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Surgery</DEPARTMENT>
<ORGANISATION>School of Medicine-Pontificia Universidad Javeriana</ORGANISATION>
<ADDRESS_1>Crra / N 42-60 of 718</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bogota</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CO">Colombia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2010-11-09 14:58:56 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<UP_TO_DATE>
<DATE DAY="20" MONTH="8" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="8" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="8" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2010-05-06 11:33:33 +0200" MODIFIED_BY="Dimitrinka Nikolova"/>
<HISTORY MODIFIED="2010-08-06 19:06:14 +0200" MODIFIED_BY="Dimitrinka Nikolova"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Pontificia Universidad Javeriana-Hospital Universitario San Ignacio</NAME>
<COUNTRY CODE="CO">Colombia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Universidad de La Sabana</NAME>
<COUNTRY CODE="CO">Colombia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-11-10 23:12:03 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SUMMARY MODIFIED="2010-11-10 15:19:14 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2010-09-17 13:17:43 +0200" MODIFIED_BY="Dimitrinka Nikolova">Antibiotic prophylaxis for elective gallbladder surgery</TITLE>
<SUMMARY_BODY MODIFIED="2010-11-10 15:19:14 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Elective gallbladder surgery is the most common elective surgical procedure in the abdomen. Antibiotic prophylaxis is a common conduct in open cholecystectomy, and it is also applied to patients undergoing laparoscopic cholecystectomy without any proof of effectiveness. Laparoscopic surgery offers some advantages related to less manipulation and shorter length of surgical wound, so antibiotic prophylaxis effect could be lower than in open surgery. This meta-analysis of eleven randomised clinical trials could not find sufficient evidence to support or refute the use of antibiotic prophylaxis to reduce surgical site infection or global infections in patients with low anaesthetic risk, low co-morbidities, and low-risk of conversion to open surgery, and undergoing elective laparoscopic cholecystectomy. This is why large and well-designed randomised trials including patients with high-risk of conversion to open surgery should be conducted in order to define the beneficial or harmful effects of the antibiotics when given as a prophylaxis.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-11-10 15:18:29 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<ABS_BACKGROUND MODIFIED="2010-11-09 15:05:07 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Cholecystectomy is a common surgical procedure. In the open cholecystectomy area, antibiotic prophylaxis showed beneficial effects, but it is not known if its benefits and harms are similar in laparoscopic cholecystectomy. Some clinical trials suggest that antibiotic prophylaxis may not be necessary in laparoscopic cholecystectomy.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>To assess the beneficial and harmful effects of antibiotic prophylaxis versus placebo or no prophylaxis for patients undergoing elective laparoscopic cholecystectomy.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-09-17 13:04:29 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We searched the<I> The Cochrane Hepato-Biliary Group Controlled Trials Register, </I>the <I>Cochrane Central Register of Controlled Trials</I> (CENTRAL) in <I>The Cochrane Library</I> (Issue 3, 2010), <I>MEDLINE</I> (1985 to August 2010), <I>EMBASE</I> (1985 to August 2010), <I>SCI-EXPANDED</I> (1985 to August 2010), <I>LILACS</I> (1988 to August 2010) as well as reference lists of relevant articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trials comparing antibiotic prophylaxis versus placebo or no prophylaxis in patients undergoing elective laparoscopic cholecystectomy.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-11-10 15:08:10 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Our outcome measures were all-cause mortality, surgical site infections, extra-abdominal infections, adverse events, and quality of life. All outcome measures were confined to within hospitalisation or 30 days after discharge. We summarised the outcome measures by reporting odds ratios and 95% confidence intervals (CI), using both the fixed-effect and the random-effects models.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We included eleven randomised clinical trials with 1664 participants who were mostly at low anaesthetic risk, low frequency of co-morbidities, low risk of conversion to open surgery, and low risk of infectious complications. None of the trials had low risk of bias. We found no statistically significant differences between antibiotic prophylaxis and no prophylaxis in the proportion of surgical site infections (odds ratio (OR) 0.87, 95% CI 0.49 to 1.54) or extra-abdominal infections (OR 0.77, 95% CI 0.41 to 1.46). Heterogeneity was not statistically significant.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-11-10 15:18:29 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>This systematic review shows that there is not sufficient evidence to support or refute the use of antibiotic prophylaxis to reduce surgical site infection and global infections in patients with low risk of anaesthetic complications, co-morbidities, conversion to open surgery, and infectious complications, and undergoing elective laparoscopic cholecystectomy. Larger randomised clinical trials with intention-to-treat analysis and patients also at high risk of conversion to open surgery are needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-11-10 23:12:03 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<BACKGROUND MODIFIED="2010-11-10 11:23:33 +0100" MODIFIED_BY="[Empty name]">
<P>Cholecystectomy is the universally accepted method to manage symptomatic uncomplicated cholelithiasis and other benign gallbladder diseases because it can cure the disease and has low morbidity and mortality (<LINK REF="REF-Keus-2010" TYPE="REFERENCE">Keus 2010</LINK>). Cholelithiasis is one of the most common abdominal diseases of adults (<LINK REF="REF-Bowen-1992" TYPE="REFERENCE">Bowen 1992</LINK>; <LINK REF="REF-Angelico-1997" TYPE="REFERENCE">Angelico 1997</LINK>). Although many patients are not symptomatic and gallbladder stones are an incidental finding during ultrasonography (<LINK REF="REF-Wenckert-1966" TYPE="REFERENCE">Wenckert 1966</LINK>; <LINK REF="REF-Gracie-1982" TYPE="REFERENCE">Gracie 1982</LINK>), 1% to 4% of patients have digestive complaints that compel a treatment (<LINK REF="REF-NIH-1993" TYPE="REFERENCE">NIH 1993</LINK>). Furthermore, biliary dyskinesia and gallbladder polyps, although less frequent, are also indications of elective cholecystectomy (<LINK REF="REF-Schwesinger-1996" TYPE="REFERENCE">Schwesinger 1996</LINK>; <LINK REF="REF-Mainprize-2000" TYPE="REFERENCE">Mainprize 2000</LINK>).</P>
<P>The most frequent complication in patients undergoing cholecystectomy is surgical site infection (<LINK REF="REF-Henry-1983" TYPE="REFERENCE">Henry 1983</LINK>). Surgical site infection was reported in 10% to 23% of the patients who had been operated on before the routine use of antibiotic prophylaxis was introduced in 1960 (<LINK REF="REF-Kaufman-1986" TYPE="REFERENCE">Kaufman 1986</LINK>; <LINK REF="REF-Chandrashekhar-1996" TYPE="REFERENCE">Chandrashekhar 1996</LINK>). The surgical site infection increases length of stay and costs and decreases the quality of life (<LINK REF="REF-Strachan-1977" TYPE="REFERENCE">Strachan 1977</LINK>; <LINK REF="REF-Morran-1978" TYPE="REFERENCE">Morran 1978</LINK>; <LINK REF="REF-Lykkegaard-1981" TYPE="REFERENCE">Lykkegaard 1981</LINK>; <LINK REF="REF-Strubbs-1983" TYPE="REFERENCE">Strubbs 1983</LINK>).</P>
<P>Since 1960, antibiotic prophylaxis has been considered as the best intervention to prevent surgical site infection in elective surgery (<LINK REF="REF-Strachan-1977" TYPE="REFERENCE">Strachan 1977</LINK>; <LINK REF="REF-Morran-1978" TYPE="REFERENCE">Morran 1978</LINK>; <LINK REF="REF-Morran-1984" TYPE="REFERENCE">Morran 1984</LINK>; <LINK REF="REF-Sykes-1984" TYPE="REFERENCE">Sykes 1984</LINK>; <LINK REF="REF-Harnoss-1985" TYPE="REFERENCE">Harnoss 1985</LINK>; <LINK REF="REF-Kaufman-1986" TYPE="REFERENCE">Kaufman 1986</LINK>). Antibiotic prophylaxis includes preoperative administration of wide-spectrum antibiotics against the most frequent bacteria involved in surgical site infection, trying to get high tissue levels of the antibiotic at the surgical wound in order to avoid colonisation and growth of microorganisms (<LINK REF="REF-Barie-2000" TYPE="REFERENCE">Barie 2000</LINK>; <LINK REF="REF-Weed-2003" TYPE="REFERENCE">Weed 2003</LINK>). It is accepted that antibiotic prophylaxis must be administered in all surgical procedures classified as clean-contaminated or in selected patients undergoing clean procedures (<LINK REF="REF-Bratzler-2004" TYPE="REFERENCE">Bratzler 2004</LINK>). Cholecystectomy is considered clean-contaminated on the basis that the biliary tract is entered without significant spillage during the procedure. Some randomised clinical trials have confirmed that antibiotic prophylaxis in open cholecystectomy is decreasing the risk of surgical site infection (<LINK REF="REF-Jewesson-1996" TYPE="REFERENCE">Jewesson 1996</LINK>; <LINK REF="REF-Lippert-1998" TYPE="REFERENCE">Lippert 1998</LINK>; <LINK REF="REF-Agrawal-1999" TYPE="REFERENCE">Agrawal 1999</LINK>).<BR/>
<BR/>Since 1986, with the original description of laparoscopic cholecystectomy, surgical treatment of benign gallbladder diseases, especially cholelithiasis, has undergone a dramatic change. Development of minimally invasive surgery for cholelithiasis showed a decrease in length of stay (<LINK REF="REF-Berggren-1994" TYPE="REFERENCE">Berggren 1994</LINK>), costs (<LINK REF="REF-Srivastava-2001" TYPE="REFERENCE">Srivastava 2001</LINK>), postoperative pain (<LINK REF="REF-McMahon-1994" TYPE="REFERENCE">McMahon 1994</LINK>), and an increase in quality of life of patients operated on (<LINK REF="REF-Barkun-1992" TYPE="REFERENCE">Barkun 1992</LINK>; <LINK REF="REF-Keus-2006" TYPE="REFERENCE">Keus 2006</LINK>). Although this surgical method diminished the length and manipulation of the surgical wound, antibiotic prophylaxis use did not change. Recent clinical trials have re-evaluated the usefulness of antibiotic prophylaxis in laparoscopic cholecystectomy (<LINK REF="STD-Illig-1997" TYPE="STUDY">Illig 1997</LINK>; <LINK REF="STD-Higgins-1999" TYPE="STUDY">Higgins 1999</LINK>; <LINK REF="STD-Harling-2000" TYPE="STUDY">Harling 2000</LINK>; <LINK REF="STD-Tocchi-2000" TYPE="STUDY">Tocchi 2000</LINK>; <LINK REF="STD-Mahatharadol-2001" TYPE="STUDY">Mahatharadol 2001</LINK>). In laparoscopic cholecystectomy the incisions are smaller than in open cholecystectomy, and the laparoscopic technique is likely associated with less risk of microbiological contamination because all manipulations of the excised organ are made through a trocar that isolates the surgical wound from the gallbladder and decreases the contact of the wound with the external environment. Nonetheless, there is no consensus about these considerations, and many surgeons still use antibiotic prophylaxis in laparoscopic cholecystectomy.</P>
<P>We found two meta-analyses investigating the beneficial and harmful effects of antibiotics when used as prophylaxis of surgical site infection in patients undergoing elective laparoscopic cholecystectomy (<LINK REF="REF-Al_x002d_Ghnaniem-2003" TYPE="REFERENCE">Al-Ghnaniem 2003</LINK>; <LINK REF="REF-Catarci-2004" TYPE="REFERENCE">Catarci 2004</LINK>). The authors concluded that antibiotic prophylaxis do not seem to offer advantages, but the meta-analyses have methodological flaws that make their conclusions prone to bias such as poor reporting of methods and inclusion of retrospective studies.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-09-16 17:57:30 +0200" MODIFIED_BY="[Empty name]">
<P>To assess the beneficial or harmful effects of antibiotic prophylaxis in patients undergoing elective laparoscopic cholecystectomy.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-11-10 15:19:58 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SELECTION_CRITERIA MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<CRIT_STUDIES MODIFIED="2010-09-21 18:02:30 +0200" MODIFIED_BY="[Empty name]">
<P>All randomised clinical trials comparing prophylactic antibiotics versus no antibiotics or placebo before laparoscopic cholecystectomy. Trials were included, irrespective of number of patients randomised, database registry, and language of the publication. Quasi-randomised trials were excluded, but data on adverse events, if available, were to be recorded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-08-06 17:07:23 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Adult patients (more than 17 years old) undergoing laparoscopic cholecystectomy with preoperative clinical diagnosis of cholelithiasis without acute cholecystitis or other benign non-acute inflammatory disease of the gallbladder. Jaundiced patients were excluded. <BR/>
</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Antibiotic prophylaxis versus placebo or no antibiotic, administered intravenously or orally, prior to elective laparoscopic surgery.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>1. All-cause mortality.<BR/>2. Surgical site infection defined according to the Centre of Disease Control (CDC) classification (<LINK REF="REF-Mangram-1999" TYPE="REFERENCE">Mangram 1999</LINK>), recorded as 'yes' or 'no'.<BR/>3. Extra-abdominal infections defined according to the CDC classification (<LINK REF="REF-Garner-1996" TYPE="REFERENCE">Garner 1996</LINK>), recorded as 'yes' or 'no'.<BR/>4. Adverse events, defined as allergic reactions to antibiotics (<LINK REF="REF-ICH_x002d_GCP-1997" TYPE="REFERENCE">ICH-GCP 1997</LINK>).<BR/>5. Quality of life.</P>
<P>All outcome measures were confined to within hospitalisation or 30 days after discharge.</P>
</CRIT_OUTCOMES_PRIMARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<ELECTRONIC_SEARCHES MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We searched <I>The Cochrane Hepato-Biliary Group Controlled Trials Register </I>(<LINK REF="REF-Gluud-2010" TYPE="REFERENCE">Gluud 2010</LINK>), the <I>Cochrane Central Register of Controlled Trials</I> (<I>CENTRAL</I>) in <I>The Cochrane Library</I>, <I>MEDLINE</I>, <I>EMBASE</I>, <I>Science Citation Index Expanded (SCI-EXPANDED)</I>, and <I>LILACS </I>(<LINK REF="REF-Royle-2003" TYPE="REFERENCE">Royle 2003</LINK>). Searches were not performed before 1985, as laparoscopic cholecystectomy was not used before 1985. Search strategies with the time span of the searches are given in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. </P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2010-11-09 14:55:02 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We wrote to authors of included trials for information on any published, unpublished, and ongoing trials. We also checked the reference lists of all the identified trials for relevant trials. Published abstracts from the conference proceedings from the American Digestive Disease Week (DDW) published in Gastroenterology and the United European Gastroenterology Week (UEGW) published in <I>Gut</I> were also handsearched. In addition, we contacted experts in the field and pharmaceutical companies and asked them to provide details of pertinent clinical trials or any relevant unpublished materials. The international societies of minimally invasive surgery (European and American Laparoscopic Surgery Society) and the international gastrointestinal surgery societies (Gastrointestinal Surgery Society) were also contacted and asked to provide information on any unpublished studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-11-10 15:19:58 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We conducted the review according to our protocol (<LINK REF="REF-Sanabria-2004" TYPE="REFERENCE">Sanabria 2004</LINK>), the recommendations of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>), and <I>The Cochrane Hepato-Biliary Group Module </I>(<LINK REF="REF-Gluud-2010" TYPE="REFERENCE">Gluud 2010</LINK>).</P>
<STUDY_SELECTION MODIFIED="2010-09-17 14:48:03 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Alvaro Sanabria (AS), Eduardo Valdivieso (EV), and Luis Dominguez (LD) extracted the data, and a consensus was sought in case of disagreement. AS and Gabriel Gomez (GG) performed the statistical analysis. We listed identified trials and made an evaluation whether the trials fulfilled the inclusion criteria. We also listed the excluded trials with the reasons for exclusion. We resolved differences among us through discussion until consensus was reached.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The following information was extracted for each trial included in this review:</P>
<OL>
<LI>Inclusion and exclusion criteria for patients being considered.</LI>
<LI>Use of prophylactic antibiotics: prophylaxis is defined as the use of antibiotic before the infection occurs and prior to surgery.</LI>
<LI>Number of randomised patients.</LI>
<LI>Number and reason of patients not randomised.</LI>
<LI>Exclusion after randomisation.</LI>
<LI>Drop-outs.</LI>
<LI>Intention-to-treat analysis.</LI>
<LI>Number of laparoscopic cholecystectomies converted to open cholecystectomies.</LI>
<LI>Adverse events.</LI>
</OL>
<P>Data on septic and non-septic abdominal complications (surgical site infections, biliary tract injury, biliary leakage), extra-abdominal complications, and number of deaths were extracted when present.</P>
<P>The statistical package Review Manager 5 (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>) provided by The Cochrane Collaboration was used. For dichotomous outcomes, the impact of the intervention was expressed as an odds ratio (OR) together with 95% confidence interval (CI). We did not have continuous variables in this review. We used a random-effects (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>) model and a fixed-effect model (<LINK REF="REF-DeMets-1987" TYPE="REFERENCE">DeMets 1987</LINK>). In case of discrepancy between the two models (eg, one giving a significant intervention effect and the other giving no significant intervention effect), we reported both results; otherwise, we reported only the results from the fixed-effect model.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-11-09 14:55:39 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Methodological quality is defined as the confidence that the design and report will restrict bias in the intervention comparison (<LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>). According to empirical evidence (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-J_x00fc_ni-2001" TYPE="REFERENCE">Jüni 2001</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>), the evaluation of the risk of bias could be achieved through assessing the following domains:</P>
<P>
<B>
<I>Allocation sequence generation</I>
</B>
</P>
<UL>
<LI>Low risk of bias: sequence generation was achieved using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice are adequate if performed by an independent adjudicator.</LI>
<LI>Uncertain risk of bias: the trial is described as randomised, but the method of sequence generation was not specified.</LI>
<LI>High risk of bias: the sequence generation method is not, or may not be, random. Quasi-randomised studies, those using dates, names, or admittance numbers in order to allocate patients are inadequate and will be excluded for the assessment of benefits but not for harms.</LI>
</UL>
<P>
<B>
<I>Allocation concealment</I>
</B>
</P>
<UL>
<LI>Low risk of bias: allocation was controlled by a central and independent randomisation unit, sequentially numbered, opaque and sealed envelopes or similar, so that intervention allocations could not have been foreseen in advance of, or during, enrolment.</LI>
<LI>Uncertain risk of bias: the trial was described as randomised but the method used to conceal the allocation was not described, so that intervention allocations may have been foreseen in advance of, or during, enrolment.</LI>
<LI>High risk of bias: if the allocation sequence was known to the investigators who assigned participants or if the study was quasi-randomised. Quasi-randomised studies will be excluded for the assessment of benefits but not for harms.</LI>
</UL>
<P>
<B>
<I>Blinding</I>
</B>
</P>
<UL>
<LI>Low risk of bias: the trial was described as blinded, the parties that were blinded, and the method of blinding was described, so that knowledge of allocation was adequately prevented during the trial.</LI>
<LI>Uncertain risk of bias: the trial was described as blind, but the method of blinding was not described, so that knowledge of allocation was possible during the trial.</LI>
<LI>High risk of bias, the trial was not blinded, so that the allocation was known during the trial.</LI>
</UL>
<P>
<B>
<I>Incomplete outcome data</I>
</B>
</P>
<UL>
<LI>Low risk of bias: the numbers and reasons for dropouts and withdrawals in all intervention groups were described or if it was specified that there were no dropouts or withdrawals.</LI>
<LI>Uncertain risk of bias: the report gave the impression that there had been no dropouts or withdrawals, but this was not specifically stated.</LI>
<LI>High risk of bias: the number or reasons for dropouts and withdrawals were not described.</LI>
</UL>
<P>
<B>
<I>Selective outcome reporting</I>
</B>
</P>
<UL>
<LI>Low risk of bias: pre-defined, or clinically relevant and reasonably expected outcomes are reported on.</LI>
<LI>Uncertain risk of bias: not all pre-defined, or clinically relevant and reasonably expected outcomes are reported on or are not reported fully, or it is unclear whether data on these outcomes were recorded or not.</LI>
<LI>High risk of bias: one or more clinically relevant and reasonably expected outcomes were not reported on; data on these outcomes were likely to have been recorded.</LI>
</UL>
<P>
<B>
<I>Vested interest bias</I>
</B>
</P>
<UL>
<LI>Low risk of bias: if there was no risk of vested interests on the side of researchers, manufacturers, or funding bodies; or any personal conflicts by the authors of the trial publication that might have unduly influenced judgements were disclosed in an honest and upright manner.</LI>
<LI>Uncertain risk of bias: if it is not possible to say that there were or there were not any financial interests on the side of researchers, manufacturers, or funding bodies reported in the trial publications.</LI>
<LI>High risk of bias: if there was risk for vested interests, eg, the trial was funded by a drug manufacturer, or researches had received money for the performance of the trial, and interests like these could have influenced the results of the trial report.</LI>
</UL>
<P>Trials with low risk of bias were considered trials that were judged as trials having 'low risk of bias' in all of the above specified individual domains. Trials with high risk of bias were considered those trials that were judged as trials having 'uncertain risk of bias' or 'high risk of bias' in one or more of the above specified individual domains.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-09-21 18:03:15 +0200" MODIFIED_BY="[Empty name]">
<P>Dichotomous data were analysed calculating the odds ratio (OR) for each trial, expressing the uncertainty with 95% confidence intervals (CI). Comparisons were made between trials evaluating antibiotic prophylaxis against no intervention or placebo administered intravenously or orally, prior to elective laparoscopic surgery.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2010-09-21 18:03:21 +0200" MODIFIED_BY="[Empty name]">
<P>Groups within the randomised clinical trial.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2010-11-10 15:19:58 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Regarding the surgical site infection, we included patients with incomplete or missing data in the sensitivity analyses by imputing them according to the following scenario.</P>
<UL>
<LI>Available case analysis: data on only those whose results are known, using as denominator the total number of patients who completed the trial. This meta-analysis was done per-protocol.</LI>
<LI>Sensitivity analysis using worst-best case analysis (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) and best-worst case analysis (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</LI>
</UL>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-09-17 15:00:24 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The chi-squared test for heterogeneity was used to provide an indication of between-study heterogeneity (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>). In addition, the degree of heterogeneity observed in the results was quantified using the I<SUP>2</SUP> statistic, which can be interpreted as the percentage of variation observed between the studies attributable to between-study differences rather than sampling error (chance).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2010-09-17 14:33:18 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We used a funnel plot to provide a visual assessment of whether treatment estimates are associated with trial size. The detection of biases varies with the magnitude of the treatment effect (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>; <LINK REF="REF-Macaskill-2001" TYPE="REFERENCE">Macaskill 2001</LINK>), the distribution of study size, and whether a one- or two-tailed test is used (<LINK REF="REF-Macaskill-2001" TYPE="REFERENCE">Macaskill 2001</LINK>). We used two tests to assess funnel plot asymmetry, adjusted rank correlation test (<LINK REF="REF-Begg-1994" TYPE="REFERENCE">Begg 1994</LINK>), and regression asymmetry test (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
</BIAS_ASSESSMENT>
<SUBGROUP_ANALYSIS MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We had planned a subgroup analysis in order to compare the intervention effect in trials with low risk of bias to that of trials with high risk of bias. Furthermore, we had planned to explore causes of heterogeneity (defined as the presence of statistical heterogeneity by chi-squared test with significance set at P value less than 0.10 and measure the quantities of heterogeneity by I<SUP>2</SUP> (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>)) by comparing different groups of trials stratified according to patient risk factors, level of experience of the surgeon, and other factors that may explain heterogeneity. Values of I<SUP>2</SUP> were categorised according to Higgins (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>): low, up to 25%; moderate, from 25 to 50% and high, higher than 75%.</P>
<P>
<B>Funnel plot</B>
<BR/>Funnel plot for selected trials is shown in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>. The adjusted rank correlation test and the regression asymmetry test were not statistically significant (intercept P value 0.42), which does not suggest bias.<BR/>
</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2010-09-17 15:14:29 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>A sensitivity analysis using worst-best case and best-worst case analyses.</LI>
</UL>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-11-10 23:12:03 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY_DESCRIPTION MODIFIED="2010-11-10 11:30:42 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2010-11-10 11:30:42 +0100" MODIFIED_BY="[Empty name]">
<P>Our searches provided fifteen studies, four of which we had to exclude. Three did not fulfil our inclusion criteria: <LINK REF="STD-Anselmi-1995" TYPE="STUDY">Anselmi 1995</LINK> was a quasi-randomised trial since the generation of the allocation sequence was based on dates; <LINK REF="STD-Uchiyama-2003" TYPE="STUDY">Uchiyama 2003</LINK> was not a randomised trial; and <LINK REF="STD-Chang-2006" TYPE="STUDY">Chang 2006</LINK> included patients with acute cholecystitis. The fourth, <LINK REF="STD-Gonzales-1996" TYPE="STUDY">Gonzales 1996</LINK>, was a thesis that we were unable to obtain. All the remaining eleven trials were randomised clinical trials with parallel designs. Ten of these trials were identified in MEDLINE and one in LILACS. Those from MEDLINE were in English, and the one from LILACS in Spanish. Authors and other sources of information did not provide further trials.</P>
<P>The inclusion criteria were similar for the selected trials: adult patients scheduled for elective laparoscopic cholecystectomy, with preoperative diagnosis of benign condition (gallbladder stones, chronic cholecystitis, cholesterolosis, or gallbladder polyps).</P>
<P>The exclusion criteria were also similar for the included trials: (a) pregnant or lactating women; (b) antibiotic allergy; (c) antibiotic therapy within 48 hours to 7 days prior to surgery; (d) clinically active infection at the moment of surgery; (e) evidence or suspicion of common bile duct stones; (f) contraindications for laparoscopic cholecystectomy; (g) indication of obligatory antibiotic prophylaxis because the medical condition was different from biliary disease (immunosuppression, corticoid use, etc). <LINK REF="STD-Csendes-1995" TYPE="STUDY">Csendes 1995</LINK>, <LINK REF="STD-Tocchi-2000" TYPE="STUDY">Tocchi 2000</LINK>, <LINK REF="STD-Kuthe-2006" TYPE="STUDY">Kuthe 2006</LINK>, <LINK REF="STD-Uludag-2009" TYPE="STUDY">Uludag 2009</LINK>, <LINK REF="STD-Yildiz-2009" TYPE="STUDY">Yildiz 2009</LINK>, and <LINK REF="STD-Sharma-2010" TYPE="STUDY">Sharma 2010</LINK> excluded patients converted to open cholecystectomy; <LINK REF="STD-Harling-2000" TYPE="STUDY">Harling 2000</LINK> excluded those who had an operative cholangiogram performed; and <LINK REF="STD-Uludag-2009" TYPE="STUDY">Uludag 2009</LINK> excluded patients older than 60 years and with American Society of Anaesthesiology (ASA) classification higher than II.<BR/>
<BR/>At the entry into the trials, participants were not reported to be different regarding age, sex, severity (measured with ASA classification), and concomitant diseases. <LINK REF="STD-Csendes-1995" TYPE="STUDY">Csendes 1995</LINK>, <LINK REF="STD-Illig-1997" TYPE="STUDY">Illig 1997</LINK>, <LINK REF="STD-Tocchi-2000" TYPE="STUDY">Tocchi 2000</LINK>, <LINK REF="STD-Mahatharadol-2001" TYPE="STUDY">Mahatharadol 2001</LINK>, <LINK REF="STD-Koc-2003" TYPE="STUDY">Koc 2003</LINK>, <LINK REF="STD-Uludag-2009" TYPE="STUDY">Uludag 2009</LINK>, and <LINK REF="STD-Sharma-2010" TYPE="STUDY">Sharma 2010</LINK> reported bile spillage or intraoperative gallbladder rupture without statistically significant differences, but <LINK REF="STD-Yildiz-2009" TYPE="STUDY">Yildiz 2009</LINK> found differences in this variable. Trials that reported ASA classification included mainly low-risk patients.<BR/>
<BR/>Interventions were prophylactic antibiotics with one preoperative dose in eight trials (<LINK REF="STD-Csendes-1995" TYPE="STUDY">Csendes 1995</LINK>; <LINK REF="STD-Higgins-1999" TYPE="STUDY">Higgins 1999</LINK>; <LINK REF="STD-Harling-2000" TYPE="STUDY">Harling 2000</LINK>; <LINK REF="STD-Mahatharadol-2001" TYPE="STUDY">Mahatharadol 2001</LINK>; <LINK REF="STD-Kuthe-2006" TYPE="STUDY">Kuthe 2006</LINK>; <LINK REF="STD-Uludag-2009" TYPE="STUDY">Uludag 2009</LINK>; <LINK REF="STD-Yildiz-2009" TYPE="STUDY">Yildiz 2009</LINK>; <LINK REF="STD-Sharma-2010" TYPE="STUDY">Sharma 2010</LINK>), or preoperative and postoperative administration less than 24 hours in three trials (<LINK REF="STD-Illig-1997" TYPE="STUDY">Illig 1997</LINK>; <LINK REF="STD-Tocchi-2000" TYPE="STUDY">Tocchi 2000</LINK>; <LINK REF="STD-Koc-2003" TYPE="STUDY">Koc 2003</LINK>). We considered these differences to be clinically not relevant, because there is a policy accepting that antibiotic prophylaxis is extended up to 24 hours. The control group was given either placebo of saline solution (<LINK REF="STD-Higgins-1999" TYPE="STUDY">Higgins 1999</LINK>; <LINK REF="STD-Tocchi-2000" TYPE="STUDY">Tocchi 2000</LINK>; <LINK REF="STD-Koc-2003" TYPE="STUDY">Koc 2003</LINK>; <LINK REF="STD-Kuthe-2006" TYPE="STUDY">Kuthe 2006</LINK>; <LINK REF="STD-Uludag-2009" TYPE="STUDY">Uludag 2009</LINK>; <LINK REF="STD-Yildiz-2009" TYPE="STUDY">Yildiz 2009</LINK>; <LINK REF="STD-Sharma-2010" TYPE="STUDY">Sharma 2010</LINK>) or no antibiotic (<LINK REF="STD-Csendes-1995" TYPE="STUDY">Csendes 1995</LINK>; <LINK REF="STD-Illig-1997" TYPE="STUDY">Illig 1997</LINK>; <LINK REF="STD-Harling-2000" TYPE="STUDY">Harling 2000</LINK>; <LINK REF="STD-Mahatharadol-2001" TYPE="STUDY">Mahatharadol 2001</LINK>). <LINK REF="STD-Harling-2000" TYPE="STUDY">Harling 2000</LINK> used a plastic bag to remove the gallbladder from the abdomen in all patients in the 'no antibiotic' group, <LINK REF="STD-Tocchi-2000" TYPE="STUDY">Tocchi 2000</LINK> and <LINK REF="STD-Uludag-2009" TYPE="STUDY">Uludag 2009</LINK> in all patients, and <LINK REF="STD-Sharma-2010" TYPE="STUDY">Sharma 2010</LINK> used it only in patients with perforated gallbladder. The antibiotics used in the trials were cefuroxime (<LINK REF="STD-Harling-2000" TYPE="STUDY">Harling 2000</LINK>; <LINK REF="STD-Kuthe-2006" TYPE="STUDY">Kuthe 2006</LINK>), cefazolin (<LINK REF="STD-Csendes-1995" TYPE="STUDY">Csendes 1995</LINK>; <LINK REF="STD-Illig-1997" TYPE="STUDY">Illig 1997</LINK>; <LINK REF="STD-Higgins-1999" TYPE="STUDY">Higgins 1999</LINK>; <LINK REF="STD-Mahatharadol-2001" TYPE="STUDY">Mahatharadol 2001</LINK>; <LINK REF="STD-Uludag-2009" TYPE="STUDY">Uludag 2009</LINK>; <LINK REF="STD-Yildiz-2009" TYPE="STUDY">Yildiz 2009</LINK>), cefotetan (<LINK REF="STD-Higgins-1999" TYPE="STUDY">Higgins 1999</LINK>), cefotaxime (<LINK REF="STD-Tocchi-2000" TYPE="STUDY">Tocchi 2000</LINK>; <LINK REF="STD-Koc-2003" TYPE="STUDY">Koc 2003</LINK>) and ceftriaxone (<LINK REF="STD-Sharma-2010" TYPE="STUDY">Sharma 2010</LINK>). In the <LINK REF="STD-Illig-1997" TYPE="STUDY">Illig 1997</LINK> trial, seven patients in the control group received antibiotics against the protocol, and antibiotics were provided to patients with higher risk of infection (inflammation and conversion to open surgery). This violation could influence the results of the trial, with a bias acting as a measure that artificially decreases the difference of surgical site infection. The <LINK REF="STD-Higgins-1999" TYPE="STUDY">Higgins 1999</LINK> trial had two antibiotic groups, one with cefazolin and one with cefotetan, which were pooled together for analysis, because both antibiotics belong to the same pharmacological family.<BR/>
<BR/>Laparoscopic surgery included skin preparation with povidone-iodine solution, use of three or four ports, creation of pneumoperitoneum, and extraction of gallbladder through the operating port, always using a bag (<LINK REF="STD-Tocchi-2000" TYPE="STUDY">Tocchi 2000</LINK>; <LINK REF="STD-Uludag-2009" TYPE="STUDY">Uludag 2009</LINK>) or at the surgeon's preference as <LINK REF="STD-Sharma-2010" TYPE="STUDY">Sharma 2010</LINK> in cases of perforated gallbladder. Incisions were closed at the end of the operation with absorbable or non-absorbable suture. <LINK REF="STD-Illig-1997" TYPE="STUDY">Illig 1997</LINK>, <LINK REF="STD-Harling-2000" TYPE="STUDY">Harling 2000</LINK>, <LINK REF="STD-Tocchi-2000" TYPE="STUDY">Tocchi 2000</LINK>, <LINK REF="STD-Koc-2003" TYPE="STUDY">Koc 2003</LINK>, <LINK REF="STD-Kuthe-2006" TYPE="STUDY">Kuthe 2006</LINK>, <LINK REF="STD-Uludag-2009" TYPE="STUDY">Uludag 2009</LINK>, <LINK REF="STD-Yildiz-2009" TYPE="STUDY">Yildiz 2009</LINK>, and <LINK REF="STD-Sharma-2010" TYPE="STUDY">Sharma 2010</LINK> took a sample of bile for culture. <LINK REF="STD-Tocchi-2000" TYPE="STUDY">Tocchi 2000</LINK> drained always the subhepatic region through the opening of a 5 mm trocar with a silicone tube, which was removed on the first postoperative day and <LINK REF="STD-Sharma-2010" TYPE="STUDY">Sharma 2010</LINK> only used a drain in cases of perforated gallbladder.</P>
<P>Infectious complications were defined clinically as fever with a clinical focus and culture positives from infectious sites, as recommended by the The Centers for Disease Control and Prevention<B> </B>(CDC) criteria for surgical site infection (<LINK REF="REF-Mangram-1999" TYPE="REFERENCE">Mangram 1999</LINK>). <LINK REF="STD-Illig-1997" TYPE="STUDY">Illig 1997</LINK>, <LINK REF="STD-Harling-2000" TYPE="STUDY">Harling 2000</LINK> and <LINK REF="STD-Uludag-2009" TYPE="STUDY">Uludag 2009</LINK> reported isolated microorganisms from each surgical site infection (SSI), without differences between groups.</P>
</SEARCH_RESULTS>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-11-10 11:30:59 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of the allocation sequence was considered of low risk of bias in three trials (<LINK REF="STD-Tocchi-2000" TYPE="STUDY">Tocchi 2000</LINK>; <LINK REF="STD-Kuthe-2006" TYPE="STUDY">Kuthe 2006</LINK>; <LINK REF="STD-Uludag-2009" TYPE="STUDY">Uludag 2009</LINK>) and high in the remaining eight. Allocation concealment was of low risk of bias in four trials (<LINK REF="STD-Higgins-1999" TYPE="STUDY">Higgins 1999</LINK>; <LINK REF="STD-Harling-2000" TYPE="STUDY">Harling 2000</LINK>; <LINK REF="STD-Uludag-2009" TYPE="STUDY">Uludag 2009</LINK>; <LINK REF="STD-Sharma-2010" TYPE="STUDY">Sharma 2010</LINK>) and high in the remaining seven trials. Seven trials (<LINK REF="STD-Higgins-1999" TYPE="STUDY">Higgins 1999</LINK>; <LINK REF="STD-Tocchi-2000" TYPE="STUDY">Tocchi 2000</LINK>; <LINK REF="STD-Koc-2003" TYPE="STUDY">Koc 2003</LINK>; <LINK REF="STD-Kuthe-2006" TYPE="STUDY">Kuthe 2006</LINK>; <LINK REF="STD-Uludag-2009" TYPE="STUDY">Uludag 2009</LINK>; <LINK REF="STD-Yildiz-2009" TYPE="STUDY">Yildiz 2009</LINK>; <LINK REF="STD-Sharma-2010" TYPE="STUDY">Sharma 2010</LINK>) used placebo. Blinded assessment was performed in seven trials classified as low risk of bias (<LINK REF="STD-Higgins-1999" TYPE="STUDY">Higgins 1999</LINK>; <LINK REF="STD-Harling-2000" TYPE="STUDY">Harling 2000</LINK>; <LINK REF="STD-Tocchi-2000" TYPE="STUDY">Tocchi 2000</LINK>; <LINK REF="STD-Koc-2003" TYPE="STUDY">Koc 2003</LINK>; <LINK REF="STD-Kuthe-2006" TYPE="STUDY">Kuthe 2006</LINK>; <LINK REF="STD-Yildiz-2009" TYPE="STUDY">Yildiz 2009</LINK>; <LINK REF="STD-Sharma-2010" TYPE="STUDY">Sharma 2010</LINK>) and three trials had high risk of bias regarding this component (<LINK REF="STD-Illig-1997" TYPE="STUDY">Illig 1997</LINK>; <LINK REF="STD-Mahatharadol-2001" TYPE="STUDY">Mahatharadol 2001</LINK>; <LINK REF="STD-Uludag-2009" TYPE="STUDY">Uludag 2009</LINK>). <LINK REF="STD-Csendes-1995" TYPE="STUDY">Csendes 1995</LINK> did not perform blinding. All trials had a low risk of bias regarding incomplete outcome data and selective outcome reporting. All trials had a high risk of bias regarding vested interest bias.</P>
<P>Follow-up was adequate in all trials, except in <LINK REF="STD-Illig-1997" TYPE="STUDY">Illig 1997</LINK>, who reported six losses to follow-up in 250 patients, and <LINK REF="STD-Mahatharadol-2001" TYPE="STUDY">Mahatharadol 2001</LINK>, who reported one loss to follow-up in 101 patients (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
<P>Intention-to-treat analysis for primary outcomes was made only in <LINK REF="STD-Illig-1997" TYPE="STUDY">Illig 1997</LINK>. Other trials excluded patients after randomisation, especially patients with non-specified protocol violations and patients who underwent conversion to open surgery, which has a higher risk of surgical site infection. We have tried to contact the authors of original trials to get information about reasons for exclusion, number and distribution of patients excluded, and outcomes of these patients. As we could not obtain more information, we made a sensitivity analysis for surgical site infection, using worst-best and best-worst scenarios for those trials reporting number of patients excluded by group. This analysis showed a high sensitivity to post-randomisation exclusions (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> and <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). Finally, all trials were of high risk of bias. <BR/>
<BR/>Sample-size estimation was only clearly described in <LINK REF="STD-Higgins-1999" TYPE="STUDY">Higgins 1999</LINK> and <LINK REF="STD-Illig-1997" TYPE="STUDY">Illig 1997</LINK>. The other trials did not report on any form of sample size calculation.<BR/>
</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-11-10 23:12:03 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>In total, 1664 patients were recruited in the eleven trials; 900 in the prophylaxis group and 764 in the no-prophylaxis group. The rate of conversion to open surgery was 2.4% in <LINK REF="STD-Higgins-1999" TYPE="STUDY">Higgins 1999</LINK>, 8.4% in <LINK REF="STD-Illig-1997" TYPE="STUDY">Illig 1997</LINK>, 3.8% in <LINK REF="STD-Harling-2000" TYPE="STUDY">Harling 2000</LINK>, and 4.1% in <LINK REF="STD-Uludag-2009" TYPE="STUDY">Uludag 2009</LINK>. <LINK REF="STD-Koc-2003" TYPE="STUDY">Koc 2003</LINK> excluded 20 of the 112 (17.8%) patients originally included in the trial because of protocol violations. <LINK REF="STD-Higgins-1999" TYPE="STUDY">Higgins 1999</LINK> excluded 38 of 450 (8.4%) patients because of protocol violations. <LINK REF="STD-Harling-2000" TYPE="STUDY">Harling 2000</LINK> excluded 30 of 106 (28.3%) patients because of the need of cholangiography, concomitant antibiotic usage, spillage of bile from gallbladder, and conversion to open surgery. <LINK REF="STD-Mahatharadol-2001" TYPE="STUDY">Mahatharadol 2001</LINK> excluded two of 102 (1.9%) patients because of lost to follow-up and protocol violation. <LINK REF="STD-Kuthe-2006" TYPE="STUDY">Kuthe 2006</LINK> excluded 11 of 104 (1.5%) patients because of intra-operative spillage, conversion to open cholecystectomy, and refusal to continue in the trial, and <LINK REF="STD-Uludag-2009" TYPE="STUDY">Uludag 2009</LINK> excluded 6 of 144 (4.1%) patients because of conversion to open surgery. <LINK REF="STD-Tocchi-2000" TYPE="STUDY">Tocchi 2000</LINK> excluded 6 of 90 (6.6%) patients, but he did not state the reasons. The other trials did not report the number of patients that were lost to follow-up. As only one trial had an intention-to-treat analysis, we performed two sensitivity analyses, using a worst-best case (a poor outcome is assigned to each treated patient for whom data were missing) and a best-worst case (a good outcome is assigned to each treated patient for whom data were missing) scenarios.<BR/>
<BR/>
<B>All-cause mortality<BR/>
</B>Mortality was not reported in any of the trials.<BR/>
<BR/>
<B>Surgical site infection</B>
<BR/>The number of surgical site infections was similar in the two groups: 24 of 900 (2.7%) patients in the prophylaxis group had a surgical site infection against 25 of 764 (3.3%) in the no-prophylaxis group. The OR was 0.87, 95% CI (0.49 to 1.54). No statistically significant differences or heterogeneity were observed (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). As I<SUP>2</SUP> values were lower than 2%, the planned analyses for heterogeneity were not necessary. The sensitivity analysis with the worst-best case scenario yields an OR of 2.80, 95% CI 1.75, 4.46, and the best-worst case scenario yields an OR of 0.34, 95% CI (0.21 to 0.54), showing a high sensitivity to post-randomisation exclusions.<BR/>
<BR/>
<B>Extra-abdominal infections</B> <B>
<BR/>
</B>Seven trials reported infectious events that are different from surgical site infections (<LINK REF="STD-Csendes-1995" TYPE="STUDY">Csendes 1995</LINK>; <LINK REF="STD-Illig-1997" TYPE="STUDY">Illig 1997</LINK>; <LINK REF="STD-Higgins-1999" TYPE="STUDY">Higgins 1999</LINK>; <LINK REF="STD-Tocchi-2000" TYPE="STUDY">Tocchi 2000</LINK>; <LINK REF="STD-Kuthe-2006" TYPE="STUDY">Kuthe 2006</LINK>; <LINK REF="STD-Uludag-2009" TYPE="STUDY">Uludag 2009</LINK>; <LINK REF="STD-Sharma-2010" TYPE="STUDY">Sharma 2010</LINK>), and these occurred in 7 of 657 (1.0%) patients in the prophylaxis group and 22 of 531 (1.8%) patients in the no-prophylaxis group. For the <LINK REF="STD-Tocchi-2000" TYPE="STUDY">Tocchi 2000</LINK> trial, we counted only four complications, although the trial refers to five events. This is because a subhepatic collection secondary to technical defect cannot be assumed as a direct outcome for antibiotic prophylaxis. The OR was 0.66 (95% CI 0.25 to 1.74). No statistically significant differences or heterogeneity were observed (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). As I<SUP>2</SUP> values were lower than 2%, the planned analyses for heterogeneity were not necessary.<BR/>
<BR/>
<B>Adverse events<BR/>
</B>Information about adverse events was not given in any of the trials.<BR/>
<BR/>
<B>Quality of life</B>
<BR/>None of the trials reported on the quality of life.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Our systematic review could not find evidence to support or refute the use of antibiotic prophylaxis for reduction of surgical site infections in patients at low risk of acquiring infections or complications when undergoing elective laparoscopic cholecystectomy when prophylactic antibiotics were administered.</P>
<P>Preliminary observations showed a decrease in surgical site infection after beginning of laparoscopic cholecystectomy when antibiotic prophylaxis was applied. So, some randomised clinical trials were designed to assess the effectiveness of antibiotic prophylaxis (<LINK REF="STD-Anselmi-1995" TYPE="STUDY">Anselmi 1995</LINK>; <LINK REF="STD-Csendes-1995" TYPE="STUDY">Csendes 1995</LINK>; <LINK REF="STD-Illig-1997" TYPE="STUDY">Illig 1997</LINK>; <LINK REF="STD-Higgins-1999" TYPE="STUDY">Higgins 1999</LINK>; <LINK REF="STD-Harling-2000" TYPE="STUDY">Harling 2000</LINK>; <LINK REF="STD-Tocchi-2000" TYPE="STUDY">Tocchi 2000</LINK>; <LINK REF="STD-Mahatharadol-2001" TYPE="STUDY">Mahatharadol 2001</LINK>; <LINK REF="STD-Koc-2003" TYPE="STUDY">Koc 2003</LINK>). However, because of the low frequency of surgical site infections and complications, each one of the trials had a small sample size to definitely probe a positive effect. Previously, <LINK REF="REF-Al_x002d_Ghnaniem-2003" TYPE="REFERENCE">Al-Ghnaniem 2003</LINK> and <LINK REF="REF-Catarci-2004" TYPE="REFERENCE">Catarci 2004</LINK> reported meta-analyses on this topic, but the first was published only as an abstract and did not allow an adequate quality assessment to be made, and the second included a retrospective study and did not include other relevant trials.</P>
<P>Our systematic review that includes eleven randomised clinical trials was not able to find significant statistical differences in the occurrence of surgical site infection and global infections between patients undergoing laparoscopic cholecystectomy who received and those who did not receive prophylactic antibiotics. However, it must be highlighted that the number of participants included in this systematic review is lower than those needed to show a real equivalence between treatments because of the low rate of outcomes. Another fact that must be realised is the lack of intention-to-treat analysis in all but one of the analysed trials. This is important to stress because trials with no intention-to- treat analyses tend to produce misleading results (<LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>). Most of the trials analysed included only patients with no protocol violations and without conversion to open surgery. This has created a selection of patients with a very low risk of surgical site infection - a reason that can explain the results for no difference between treatments. The sensitivity analysis showed a high dependence of results related with post-randomisation exclusions, which supports even more the potential risk of bias of our finding. If one shall apply these findings to all patients who are going to undergo elective laparoscopic cholecystectomy is still a matter of personal judgement until a definite recommendation could be given.</P>
<P>Conductance of more clinical trials with low risk of bias must be considered in order to increase the sample size and to surpass methodological weaknesses found in this review. A future randomised trial will need a sample size of approximately 3500 patients by intervention group. Neither clinical heterogeneity nor statistical heterogeneity were identified in the relevant clinical variables of the trials included, so it could be that the compared patients were similar. Since many of the risk of bias criteria were not clearly reported, we cannot be sure that bias did not have an effect in the trials. We believe that lost to follow-up, found in <LINK REF="STD-Illig-1997" TYPE="STUDY">Illig 1997</LINK> and <LINK REF="STD-Mahatharadol-2001" TYPE="STUDY">Mahatharadol 2001</LINK>, was minimal and do not introduce important bias to the results, but as previously commented, the lack of intention-to-treat analysis makes this conclusion difficult to apply to all candidates to laparoscopic cholecystectomy.</P>
<P>Another important point to discuss is the individual risk of the patients. The included trials had selected mainly patients at low risk of acquiring an infection, making its management reasonably simple, and the life of the patient was not compromised. However, this statement cannot be applied to high-risk patients as those prone to conversion to open surgery, those with co-morbidities and those with high anaesthetic risk scores as ASA, for whom these conditions are not accomplished, and an infection could cause the death of the patient. In relation to the generalisability of the results, it is important to highlight this concern. New trials including patients at high risk of acquiring infections from the laparoscopic cholecystectomy intervention are necessary to confirm the finding of no difference in effect. The existing clinical trials suggest that antibiotic prophylaxis in laparoscopic cholecystectomy may not be needed for patients at low risk of acquiring infections or complications and with low risk of conversion to open surgery, and that each patient undergoing surgery must be assessed carefully when selecting the therapy.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<IMPLICATIONS_PRACTICE MODIFIED="2010-08-06 18:52:28 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>With the present data, the evidence does not support or refute the use of antibiotic prophylaxis to reduce surgical site infection in low-risk patients undergoing laparoscopic cholecystectomy. The use of prophylactic antibiotics administration must be selected individually in those patients with medium or high risk.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>It is necessary to conduct randomised clinical trials with large sample sizes to get enough number of patients and outcomes to probe the equivalence between treatments. Moreover, it is also necessary to asses this assumption in high-risk patients. Reporting requirements of randomised clinical trials as suggested by the CONSORT statement (www.consort-statement.org) should be strictly applied, since lack of good reporting could wrongly decrease the methodological quality of surgical randomised clinical trials.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-11-09 14:57:01 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>To Dimitrinka Nikolova, Managing Editor, Cochrane Hepato-Biliary Group for help in the development of this review.</P>
<P>Peer Reviewers: Tahany Awad, Denmark; Kurinchi Gurusamy, UK; Frederik Keus, The Netherlands.<BR/>Contact Editor: Christian Gluud, Denmark.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-10-08 18:10:31 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>AE Sanabria: conceiving, designing, and co-ordination of the review.</P>
<P>AE Sanabria, E Valdivieso, and G Gomez: developing of search strategy; undertaking searches; screening search results; management of papers retrieval; screening of retrieved papers against inclusion criteria; writing to authors of papers for additional information; collecting data for the review; providing of additional data about papers; management of data for the review; appraising quality of papers; abstracting data from papers; analysing of data; interpreting data; providing a methodological perspective; providing a clinical perspective; and writing the review.</P>
<P>L Dominguez: undertaking searches; screening search results; screening of retrieved papers against inclusion criteria; collecting data for the review; providing of additional data about papers; appraising quality of papers; abstracting data from papers; interpreting data; providing a clinical perspective; and writing the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-11-05 13:39:56 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>As the protocol for this review was published in 2004, we had to update it following the guidelines in the Reviewer's Handbook (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>) before starting our work on the review. The changes we have made refer to the risk of bias and order of the outcomes.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-11-10 11:23:08 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-09-17 17:38:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<INCLUDED_STUDIES MODIFIED="2010-09-16 18:10:15 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Csendes-1995" NAME="Csendes 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Csendes A, Silva A, Burdiles P, Diaz J, Korn O, Maluenda F</AU>
<TI>Antibiotic prophylaxis in laparoscopic cholecystectomy: prospective randomized trial</TI>
<TO>Profilaxis antibiotica en colecistectomia laparoscopica: estudio prospectivo randomizado</TO>
<SO>Revista Chilena de Cirugia</SO>
<YR>1995</YR>
<VL>47</VL>
<PG>145-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harling-2000" NAME="Harling 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harling R, Moorjani N, Perry C, MacGowan AP, Thompson MH</AU>
<TI>A prospective, randomised trial of prophylactic antibiotics versus bag extraction in the prophylaxis of wound infection in laparoscopic cholecystectomy</TI>
<SO>Annals of the Royal College of Surgeons of England</SO>
<YR>2000</YR>
<VL>82</VL>
<PG>408-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Higgins-1999" NAME="Higgins 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Higgins A, London J, Charland S, Ratzer E, Clark J, Haun W, et al</AU>
<TI>Prophylactic antibiotics for elective laparoscopic cholecystectomy: are they necessary?</TI>
<SO>Archives of Surgery</SO>
<YR>1999</YR>
<VL>134</VL>
<PG>611-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Illig-1997" NAME="Illig 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Illig KA, Schmidt E, Cavanaugh J, Krusch D, Sax HC</AU>
<TI>Are prophylactic antibiotics required for elective laparoscopic cholecystectomy?</TI>
<SO>Journal of the American College of Surgeons</SO>
<YR>1997</YR>
<VL>184</VL>
<PG>353-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koc-2003" NAME="Koc 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koc M, Zulfikaroglu B, Kece C, Ozalp N</AU>
<TI>A prospective randomized study of prophylactic antibiotics in elective laparoscopic cholecystectomy</TI>
<SO>Surgical Endoscopy</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>1716-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuthe-2006" MODIFIED="2010-09-10 12:08:00 +0200" MODIFIED_BY="[Empty name]" NAME="Kuthe 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-09-10 12:08:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuthe S, Kaman L, Verma G, Singh R</AU>
<TI>Evaluation of the role of prophylactic antibiotics in elective laparoscopic cholecystectomy: a prospective randomized trial</TI>
<SO>Tropical Gastroenterology</SO>
<YR>2006</YR>
<VL>27</VL>
<PG>54-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahatharadol-2001" NAME="Mahatharadol 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahatharadol V</AU>
<TI>A reevaluation of antibiotic prophylaxis in laparoscopic cholecystectomy: a randomized controlled trial</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>2001</YR>
<VL>84</VL>
<PG>105-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-2010" MODIFIED="2010-09-10 12:08:45 +0200" MODIFIED_BY="[Empty name]" NAME="Sharma 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-09-10 12:08:45 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma N, Garg P, Hadke N, Choudhary D</AU>
<TI>Role of prophylactic antibiotics in laparoscopic cholecystectomy and risk factors for surgical site infection: A randomized controlled trial</TI>
<SO>Surgical Infections</SO>
<YR>2010</YR>
<VL>11</VL>
<NO>4</NO>
<PG>367-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tocchi-2000" NAME="Tocchi 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tocchi A, Lepre L, Costa G, Liotta G, Mazzoni G, Maggiolini F</AU>
<TI>The need for antibiotic prophylaxis in elective laparoscopic cholecystectomy: a prospective randomized study</TI>
<SO>Archives of Surgery</SO>
<YR>2000</YR>
<VL>135</VL>
<PG>67-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uludag-2009" MODIFIED="2010-09-10 12:09:04 +0200" MODIFIED_BY="[Empty name]" NAME="Uludag 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-09-10 12:09:04 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uludag M, Yetkin G, Citgez B</AU>
<TI>The role of prophylactic antibiotics in elective laparoscopic cholecystectomy</TI>
<SO>Journal of the Society of Laparoendoscopic Surgeons</SO>
<YR>2009</YR>
<VL>13</VL>
<PG>337-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yildiz-2009" MODIFIED="2010-09-16 18:10:15 +0200" MODIFIED_BY="[Empty name]" NAME="Yildiz 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-09-16 18:10:15 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yildiz B, Abbasoglu O, Tirnaksiz B, Hamaloglu E, Ozdemyr A, Sayek I</AU>
<TI>Determinants of postoperative infection after laparoscopic cholecystectomy</TI>
<SO>Hepato-Gastroenterology</SO>
<YR>2009</YR>
<VL>56</VL>
<PG>589-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-09-17 17:38:25 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY DATA_SOURCE="PUB" ID="STD-Anselmi-1995" MODIFIED="2010-09-17 17:38:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Anselmi 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-09-16 20:11:10 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anselmi M, Duran R, Acuna J, Zambrano C</AU>
<TI>Laparoscopic cholecystectomy: antibiotic prophylaxis is useful in chronic cholecystitis</TI>
<TO>Colecistectomia laparoscopica: es util la profilaxis antibiotica en colecistitis cronica?</TO>
<SO>Revista Chilena de Cirugia</SO>
<YR>1995</YR>
<VL>47</VL>
<PG>30-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-09-17 17:38:25 +0200" MODIFIED_BY="Dimitrinka Nikolova"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chang-2006" MODIFIED="2010-09-10 12:10:08 +0200" MODIFIED_BY="[Empty name]" NAME="Chang 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-09-10 12:10:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chang WT, Lee KT, Chuang SC, Wang SN, Kuo KK, Chen JS, et al</AU>
<TI>The impact of prophylactic antibiotics on postoperative infection complication in elective laparoscopic cholecystectomy: a prospective randomized study</TI>
<SO>American Journal of Surgery</SO>
<YR>2006</YR>
<VL>191</VL>
<PG>721-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonzales-1996" NAME="Gonzales 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Gonzales M</AU>
<TI>Antibiotic prophylaxis with sodic cefazolin in patients with cholecystitis and submitted to cholecystectomy at the Hospital Regional Honorio Delgado</TI>
<TO>Antibioticoprofilaxis con cefazolina sodica en pacientes colecistectomizados por colecistitis en el Hospital Regional Honorio Delgado</TO>
<SO>Tesis Universidad Nacional de San Agustin. Arequipa. Peru</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uchiyama-2003" MODIFIED="2010-09-10 12:10:55 +0200" MODIFIED_BY="[Empty name]" NAME="Uchiyama 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-09-10 12:10:55 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uchiyama K, Kawai M, Onishi H, Tani M, Kinoshita H, Ueno M, et al</AU>
<TI>Preoperative antimicrobial administration for prevention of postoperative infection in patients with laparoscopic cholecystectomy</TI>
<SO>Digestive Disease and Sciences</SO>
<YR>2003</YR>
<VL>10</VL>
<PG>1955-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-11-10 11:23:08 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-11-10 11:23:08 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Agrawal-1999" MODIFIED="2008-10-27 14:02:02 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Agrawal 1999" TYPE="JOURNAL_ARTICLE">
<AU>Agrawal CS, Sehgal R, Singh RK, Gupta AK</AU>
<TI>Antibiotic prophylaxis in elective cholecystectomy: a randomized, double blinded study comparing ciprofloxacin and cefuroxime</TI>
<SO>Indian Journal of Physiology and Pharmacology</SO>
<YR>1999</YR>
<VL>43</VL>
<PG>501-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Al_x002d_Ghnaniem-2003" MODIFIED="2008-10-27 14:03:55 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Al-Ghnaniem 2003" TYPE="JOURNAL_ARTICLE">
<AU>Al-Ghnaniem R, Benjamin IS, Patel AG</AU>
<TI>Meta-analysis suggests antibiotic prophylaxis is not warranted in low-risk patients undergoing laparoscopic cholecystectomy</TI>
<SO>British Journal of Surgery</SO>
<YR>2003</YR>
<VL>90</VL>
<PG>365-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Angelico-1997" MODIFIED="2008-10-27 14:02:02 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Angelico 1997" TYPE="JOURNAL_ARTICLE">
<AU>Angelico F, Del Ben M, Barbato A, Conti R, Urbinati G</AU>
<TI>Ten-year incidence and natural history of gallstone disease in a rural population of women in central Italy. The Rome Group for the Epidemiology and Prevention of Cholelithiasis (GREPCO)</TI>
<SO>Italian Journal of Gastroenterology and Hepatology</SO>
<YR>1997</YR>
<VL>29</VL>
<PG>249-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barie-2000" MODIFIED="2008-10-27 14:02:02 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Barie 2000" TYPE="JOURNAL_ARTICLE">
<AU>Barie PS</AU>
<TI>Modern surgical antibiotic prophylaxis and therapy - less is more</TI>
<SO>Surgical Infections</SO>
<YR>2000</YR>
<VL>1</VL>
<PG>23-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barkun-1992" MODIFIED="2008-10-27 14:02:02 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Barkun 1992" TYPE="JOURNAL_ARTICLE">
<AU>Barkun JS, Barkun AN, Sampalis JS, Fried G, Taylor B, Wexler MJ, et al</AU>
<TI>Randomised controlled trial of laparoscopic versus mini cholecystectomy. The McGill Gallstone Treatment Group</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>340</VL>
<PG>1116-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1994" MODIFIED="2008-10-27 14:02:02 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Begg 1994" TYPE="JOURNAL_ARTICLE">
<AU>Begg CB, Mazumdar M</AU>
<TI>Operating characteristics of a rank correlation test for publication bias</TI>
<SO>Biometrics</SO>
<YR>1994</YR>
<VL>50</VL>
<PG>1088-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berggren-1994" MODIFIED="2008-10-27 14:02:02 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Berggren 1994" TYPE="JOURNAL_ARTICLE">
<AU>Berggren U, Gordh T, Grama D, Haglund U, Rastad J, Arvidsson D</AU>
<TI>Laparoscopic versus open cholecystectomy: hospitalization, sick leave, analgesia and trauma responses</TI>
<SO>British Journal of Surgery</SO>
<YR>1994</YR>
<VL>81</VL>
<PG>1362-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bowen-1992" MODIFIED="2008-10-27 14:02:02 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Bowen 1992" TYPE="JOURNAL_ARTICLE">
<AU>Bowen JC, Brenner HI, Ferrante WA, Maule WF</AU>
<TI>Gallstone disease. Pathophysiology, epidemiology, natural history, and treatment options</TI>
<SO>Medical Clinics of North America</SO>
<YR>1992</YR>
<VL>76</VL>
<PG>1143-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bratzler-2004" MODIFIED="2010-09-16 18:12:14 +0200" MODIFIED_BY="[Empty name]" NAME="Bratzler 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bratzler DW, Houck PM; Surgical Infection Prevention Guidelines Writers Workgroup; American Academy of Orthopaedic Surgeons; American Association of Critical Care Nurses; American Association of Nurse Anesthetists; American College of Surgeons; American College of Osteopathic Surgeons; American Geriatrics Society; American Society of Anesthesiologists; American Society of Colon and Rectal Surgeons; American Society of Health-System Pharmacists; American Society of PeriAnesthesia Nurses; Ascension Health; Association of periOperative Registered Nurses; Association for Professionals in Infection Control and Epidemiology; Infectious Diseases Society of America; Medical Letter; Premier; Society for Healthcare Epidemiology of America; Society of Thoracic Surgeons; Surgical Infection Society</AU>
<TI>Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2004</YR>
<VL>38</VL>
<PG>1706-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Catarci-2004" MODIFIED="2008-10-27 14:03:55 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Catarci 2004" TYPE="JOURNAL_ARTICLE">
<AU>Catarci M, Mancini S, Gentileschi P, Camplone C, Sileri P, Grassi G</AU>
<TI>Antibiotic prophylaxis in elective laparoscopic cholecystectomy. Lack of need or lack of evidence?</TI>
<SO>Surgical Endoscopy</SO>
<YR>2004</YR>
<VL>18</VL>
<PG>638-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chandrashekhar-1996" MODIFIED="2010-09-10 12:13:34 +0200" MODIFIED_BY="[Empty name]" NAME="Chandrashekhar 1996" TYPE="JOURNAL_ARTICLE">
<AU>Chandrashekhar C, Seenu V, Misra MC, Rattan A, Kapur BM, Singh R</AU>
<TI>Risk factors for wound infection following elective cholecystectomy</TI>
<SO>Tropical Gastroenterology</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>230-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeMets-1987" MODIFIED="2010-11-08 17:49:17 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="DeMets 1987" TYPE="JOURNAL_ARTICLE">
<AU>DeMets DL</AU>
<TI>Methods for combining randomized clinical trials: strengths and limitations</TI>
<SO>Statistics in Medicine</SO>
<YR>1987</YR>
<VL>6</VL>
<PG>341-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2010-09-16 18:13:12 +0200" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2010-09-16 18:13:53 +0200" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garner-1996" MODIFIED="2010-09-10 12:53:53 +0200" MODIFIED_BY="[Empty name]" NAME="Garner 1996" TYPE="BOOK">
<AU>Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM</AU>
<SO>APIC Infection Control and Applied Epidemiology: Principles and Practice</SO>
<YR>1996</YR>
<EN>First</EN>
<PB>Mosby</PB>
<CY>St Louis</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2010" MODIFIED="2010-09-10 11:50:52 +0200" MODIFIED_BY="[Empty name]" NAME="Gluud 2010" TYPE="OTHER">
<AU>Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al</AU>
<TI>Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs))</TI>
<SO>2010, Issue 8. Art. No.: LIVER</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gracie-1982" MODIFIED="2009-04-19 03:04:23 +0200" MODIFIED_BY="[Empty name]" NAME="Gracie 1982" TYPE="JOURNAL_ARTICLE">
<AU>Gracie WA, Ranshohoff SL, Williamson RC</AU>
<TI>The natural history of silent gallstones. The innocent gallstones is not a myth</TI>
<SO>New England Journal of Medicine</SO>
<YR>1982</YR>
<VL>307</VL>
<PG>798-800</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harnoss-1985" MODIFIED="2010-09-16 18:24:10 +0200" MODIFIED_BY="[Empty name]" NAME="Harnoss 1985" TYPE="JOURNAL_ARTICLE">
<AU>Harnoss BM, Hirner A, Kruselmann M, Haring R, Lode H</AU>
<TI>Antibiotic infection prophylaxis in gallbladder surgery-a prospective randomized study</TI>
<SO>Chemotherapy</SO>
<YR>1985</YR>
<VL>31</VL>
<NO>1</NO>
<PG>76-82</PG>
<IDENTIFIERS MODIFIED="2008-11-10 23:32:46 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="3882356"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Henry-1983" MODIFIED="2010-09-10 12:15:22 +0200" MODIFIED_BY="[Empty name]" NAME="Henry 1983" TYPE="JOURNAL_ARTICLE">
<AU>Henry ML, Carey LC</AU>
<TI>Complications of cholecystectomy</TI>
<SO>Surgical Clinics of North America</SO>
<YR>1983</YR>
<VL>63</VL>
<PG>1191-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2010-09-16 18:15:13 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2010-09-10 12:16:32 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2009" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]</TI>
<SO>The Cochrane Colloboration, 2009. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICH_x002d_GCP-1997" MODIFIED="2010-11-03 14:54:17 +0100" MODIFIED_BY="[Empty name]" NAME="ICH-GCP 1997" TYPE="BOOK">
<AU>International Conference on Harmonisation Expert Working Group</AU>
<SO>International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice1997 CFR &amp; ICH Guidelines</SO>
<YR>1997</YR>
<VL>1</VL>
<PB>Barnett International/PAREXEL</PB>
<CY>PA 19063-2043, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jewesson-1996" MODIFIED="2008-10-27 14:02:02 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Jewesson 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jewesson PJ, Stiver G, Wai A, Frighetto L, Nickoloff D, Smith J, et al</AU>
<TI>Double-blind comparison of cefazolin and ceftizoxime for prophylaxis against infections following elective biliary tract surgery</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1996</YR>
<VL>40</VL>
<PG>70-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-2001" MODIFIED="2010-09-16 18:15:33 +0200" MODIFIED_BY="[Empty name]" NAME="Jüni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Altman DG, Egger M</AU>
<TI>Systematic reviews in health care: Assessing the quality of controlled clinical trials</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2001</YR>
<VL>323</VL>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaufman-1986" MODIFIED="2010-09-16 18:23:13 +0200" MODIFIED_BY="[Empty name]" NAME="Kaufman 1986" TYPE="JOURNAL_ARTICLE">
<AU>Kaufman Z, Dinbar A</AU>
<TI>Single dose prophylaxis in elective cholecystectomy. A prospective, double-blind randomized study</TI>
<SO>American Journal of Surgery</SO>
<YR>1986</YR>
<VL>152</VL>
<NO>5</NO>
<PG>513-6</PG>
<IDENTIFIERS MODIFIED="2008-11-10 23:32:46 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="3777330"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Keus-2006" MODIFIED="2010-09-16 18:16:58 +0200" MODIFIED_BY="[Empty name]" NAME="Keus 2006" TYPE="COCHRANE_REVIEW">
<AU>Keus F, de Jong JA, Gooszen HG, van Laarhoven CJ</AU>
<TI>Laparoscopic versus open cholecystectomy for patients with symptomatic cholecystolithiasis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-09-10 12:21:38 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-10 12:21:38 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006231"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Keus-2010" MODIFIED="2010-11-10 11:23:07 +0100" MODIFIED_BY="[Empty name]" NAME="Keus 2010" TYPE="COCHRANE_REVIEW">
<AU>Keus F, Gooszen HG, van Laarhoven CJHM</AU>
<TI>Open, small-incision, or laparoscopic cholecystectomy for patients with symptomatic cholecystolithiasis. An overview of Cochrane Hepato-Biliary Group reviews</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-11-10 11:23:07 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-11-10 11:23:07 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008318"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2008-10-27 14:02:02 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Kjaergard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<PG>982-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lippert-1998" MODIFIED="2008-10-27 14:02:02 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Lippert 1998" TYPE="JOURNAL_ARTICLE">
<AU>Lippert H, Gastinger J</AU>
<TI>Antimicrobial prophylaxis in laparoscopic and conventional cholecystectomy. Conclusions of a large prospective multicenter quality assurance study in Germany</TI>
<SO>Chemotherapy</SO>
<YR>1998</YR>
<VL>44</VL>
<PG>355-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lykkegaard-1981" MODIFIED="2010-09-16 18:17:32 +0200" MODIFIED_BY="[Empty name]" NAME="Lykkegaard 1981" TYPE="JOURNAL_ARTICLE">
<AU>Lykkegaard Nielsen M, Moesgaard F, Justesen T, Scheibel JH, Lindenberg S</AU>
<TI>Wound sepsis after elective cholecystectomy. Restriction of prophylactic antibiotics to risk groups</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>1981</YR>
<VL>16</VL>
<PG>937-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Macaskill-2001" MODIFIED="2008-10-27 14:02:02 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Macaskill 2001" TYPE="JOURNAL_ARTICLE">
<AU>Macaskill P, Walter SD, Irwig L</AU>
<TI>A comparison of methods to detect publication bias in meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>641-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mainprize-2000" MODIFIED="2010-09-10 12:22:19 +0200" MODIFIED_BY="[Empty name]" NAME="Mainprize 2000" TYPE="JOURNAL_ARTICLE">
<AU>Mainprize KS, Gould SW, Gilbert JM</AU>
<TI>Surgical management of polypoid lesions of the gallbladder</TI>
<SO>British Journal of Surgery</SO>
<YR>2000</YR>
<VL>87</VL>
<PG>414-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mangram-1999" MODIFIED="2010-11-03 15:02:43 +0100" MODIFIED_BY="[Empty name]" NAME="Mangram 1999" TYPE="JOURNAL_ARTICLE">
<AU>Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR</AU>
<TI>Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee</TI>
<SO>Infection control and hospital epidemiology</SO>
<YR>1999</YR>
<VL>20</VL>
<PG>250-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McMahon-1994" MODIFIED="2010-09-16 18:18:23 +0200" MODIFIED_BY="[Empty name]" NAME="McMahon 1994" TYPE="JOURNAL_ARTICLE">
<AU>McMahon AJ, Russell IT, Ramsay G, Sunderland G, Baxter JN, Anderson JR, et al</AU>
<TI>Laparoscopic and minilaparotomy cholecystectomy: a randomized trial comparing postoperative pain and pulmonary function</TI>
<SO>Surgery</SO>
<YR>1994</YR>
<VL>115</VL>
<NO>5</NO>
<PG>533-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2008-10-27 14:02:02 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morran-1978" MODIFIED="2010-09-16 18:18:56 +0200" MODIFIED_BY="[Empty name]" NAME="Morran 1978" TYPE="JOURNAL_ARTICLE">
<AU>Morran C, McNaught W, McArdle CS</AU>
<TI>Prophylactic co-trimoxazole in biliary surgery</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>1978</YR>
<VL>2</VL>
<PG>462-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morran-1984" MODIFIED="2010-09-10 12:23:40 +0200" MODIFIED_BY="[Empty name]" NAME="Morran 1984" TYPE="JOURNAL_ARTICLE">
<AU>Morran CG, Thomson G, White A, McNaught W, Smith DC, McArdle CS</AU>
<TI>Wound sepsis after low risk elective cholecystectomy: the effect of cefuroxime</TI>
<SO>British Journal of Surgery</SO>
<YR>1984</YR>
<VL>71</VL>
<NO>7</NO>
<PG>540-2</PG>
<IDENTIFIERS MODIFIED="2008-11-10 23:32:46 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="6375802"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NIH-1993" MODIFIED="2010-09-10 12:23:54 +0200" MODIFIED_BY="[Empty name]" NAME="NIH 1993" TYPE="JOURNAL_ARTICLE">
<AU>National Institutes of Health</AU>
<TI>National Institutes of Health Consensus Development Conference Statement on Gallstones and Laparoscopic Cholecystectomy</TI>
<SO>American Journal of Surgery</SO>
<YR>1993</YR>
<VL>165</VL>
<PG>390-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2010-09-10 11:50:52 +0200" MODIFIED_BY="[Empty name]" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Royle-2003" MODIFIED="2010-09-10 11:50:52 +0200" MODIFIED_BY="[Empty name]" NAME="Royle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Royle P, Milne R</AU>
<TI>Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>4</NO>
<PG>591-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sanabria-2004" MODIFIED="2010-09-16 18:19:14 +0200" MODIFIED_BY="[Empty name]" NAME="Sanabria 2004" TYPE="COCHRANE_PROTOCOL">
<AU>Sanabria A, Valdivieso E, Gomez G</AU>
<TI>Antibiotic prophylaxis for patients undergoing elective laparoscopic cholecystectomy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-09-10 12:38:54 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-10 12:38:54 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005265"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-10-27 14:02:02 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schwesinger-1996" MODIFIED="2010-09-10 12:39:16 +0200" MODIFIED_BY="[Empty name]" NAME="Schwesinger 1996" TYPE="JOURNAL_ARTICLE">
<AU>Schwesinger WH, Diehl AK</AU>
<TI>Changing indications for laparoscopic cholecystectomy. Stones without symptoms and symptoms without stones</TI>
<SO>Surgical Clinics of North America</SO>
<YR>1996</YR>
<VL>76</VL>
<PG>493-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Srivastava-2001" MODIFIED="2010-09-16 18:19:39 +0200" MODIFIED_BY="[Empty name]" NAME="Srivastava 2001" TYPE="JOURNAL_ARTICLE">
<AU>Srivastava A, Srinivas G, Misra MC, Pandav CS, Seenu V, Goyal A</AU>
<TI>Cost-effectiveness analysis of laparoscopic versus minilaparotomy cholecystectomy for gallstone disease. A randomized trial</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2001</YR>
<VL>17</VL>
<NO>4</NO>
<PG>497-502</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Strachan-1977" MODIFIED="2010-09-16 18:20:13 +0200" MODIFIED_BY="[Empty name]" NAME="Strachan 1977" TYPE="JOURNAL_ARTICLE">
<AU>Strachan CJ, Black J, Powis SJ, Waterworth TA, Wise R, Wilkinson AR, et al</AU>
<TI>Prophylactic use of cephazolin against wound sepsis after cholecystectomy</TI>
<SO>British Medical Journal</SO>
<YR>1977</YR>
<VL>1</VL>
<PG>124-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Strubbs-1983" MODIFIED="2010-09-16 18:20:34 +0200" MODIFIED_BY="[Empty name]" NAME="Strubbs 1983" TYPE="JOURNAL_ARTICLE">
<AU>Stubbs RS</AU>
<TI>Wound infection after cholecystectomy: a case for routine prophylaxis</TI>
<SO>Annals of the Royal College of Surgeons of England</SO>
<YR>1983</YR>
<VL>65</VL>
<PG>30-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sykes-1984" MODIFIED="2010-11-03 15:03:41 +0100" MODIFIED_BY="[Empty name]" NAME="Sykes 1984" TYPE="JOURNAL_ARTICLE">
<AU>Sykes D, Basu PK</AU>
<TI>Prophylactic use of cefotaxime in elective biliary surgery</TI>
<SO>The Journal of Antimicrobial Chemotherapy</SO>
<YR>1984</YR>
<VL>14</VL>
<NO>Suppl B</NO>
<PG>237-9</PG>
<IDENTIFIERS MODIFIED="2008-11-10 23:32:46 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="6094446"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Weed-2003" MODIFIED="2008-10-27 14:02:02 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Weed 2003" TYPE="JOURNAL_ARTICLE">
<AU>Weed HG</AU>
<TI>Antimicrobial prophylaxis in the surgical patient</TI>
<SO>Medical Clinics of North America</SO>
<YR>2003</YR>
<VL>87</VL>
<PG>59-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wenckert-1966" MODIFIED="2010-09-16 18:21:41 +0200" MODIFIED_BY="[Empty name]" NAME="Wenckert 1966" TYPE="JOURNAL_ARTICLE">
<AU>Wenckert A, Robertson B</AU>
<TI>The natural course of gallstone disease. Eleven year review of 781 non operated cases</TI>
<SO>Gastroenterology</SO>
<YR>1966</YR>
<VL>50</VL>
<PG>376-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2010-09-16 18:22:21 +0200" MODIFIED_BY="[Empty name]" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-11-09 15:04:23 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-11-09 15:04:23 +0100" MODIFIED_BY="Dimitrinka Nikolova" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-11-09 15:01:44 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Csendes-1995">
<CHAR_METHODS MODIFIED="2008-11-13 23:07:20 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial with a parallel design.</P>
<P>Generation of the allocation sequence: unclear.</P>
<P>Allocation concealment: unclear.</P>
<P>Blinding: not performed. Outcome assessment was made by surgeons of the treatment group, but it was not stated if they were blinded.</P>
<P>Follow-up: adequate; without lost to follow-up at 15 days.</P>
<P>Intention-to-treat analysis: no.</P>
<P>Sample size calculations: no.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-08 18:10:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>105 patients randomised (50 for antibiotic group and 55 for no-antibiotic group).</P>
<P>Sex: 32 men/73 women.</P>
<P>Mean age 48.1 to 49.3. Age of inclusion not reported.</P>
<P>Inclusion criteria: clinical diagnosis of chronic cholecystitis undergoing elective cholecystectomy.</P>
<P>Exclusions criteria: conversion to open surgery and acute cholecystitis.</P>
<P>Trial duration: 14 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intravenous single cefazolin dose, 1 g given at the time of induction compared with no antibiotic in the control group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Surgical site infection determined by pus drainage and extra-abdominal infections.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-09 15:01:44 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Contacted authors April 9/2007. It was impossible to get more information about excluded patients because data were not available.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-09 15:02:00 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Harling-2000">
<CHAR_METHODS MODIFIED="2010-11-09 15:02:00 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trial with a parallel design.</P>
<P>Generation of the allocation sequence: unclear.</P>
<P>Allocation concealment: adequate; sealed envelopes.</P>
<P>Blinding: single-blind. Outcome assessment was made by surgeons of the treatment group blind to intervention.</P>
<P>Follow-up: adequate: without lost to follow-up (time not stated).</P>
<P>Intention-to-treat analysis: no.</P>
<P>Sample size calculations: no.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-02 00:35:16 +0100" MODIFIED_BY="[Empty name]">
<P>76 patients (39 for antibiotic group and 37 for no-antibiotic group).</P>
<P>Sex distribution not reported.</P>
<P>Mean age not reported. Age of inclusion not reported.</P>
<P>Inclusion criteria: patients undergoing elective cholecystectomy.</P>
<P>Exclusions criteria: need to carry out cholangiography, concomitant usage of antibiotics, spillage of gallbladder content, and conversion to open surgery.</P>
<P>Trial duration: 14 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intravenous single cefuroxime dose, 750 mg given at the time of induction compared with removing of the gallbladder with a plastic bag.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Surgical site infection determined by pus drainage.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Higgins-1999">
<CHAR_METHODS>
<P>Randomised clinical trial with a parallel design.</P>
<P>Generation of the allocation sequence: unclear. </P>
<P>Allocation concealment: adequate; sealed envelopes. </P>
<P>Blinding: double-blind. Use of placebo. Outcome assessment was made by surgeons of the treatment group blind to intervention. </P>
<P>Follow-up: adequate: without lost to follow-up at 30 days.</P>
<P>Intention-to-treat analysis: no.</P>
<P>Sample size calculations: yes. Power of 80%, alfa error of 5%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-21 16:24:23 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>412 patients (277 for antibiotics groups and 135 for placebo).</P>
<P>Sex distribution not reported.</P>
<P>Mean age: 47.1 to 48.2. Age of inclusion 18 to 80.</P>
<P>Inclusion criteria: patients scheduled to elective cholecystectomy.</P>
<P>Exclusions criteria: pregnant or lactating women, antibiotic allergy, previous antibiotic therapy, acute cholecystitis or cholangitis, jaundice, previous biliary surgery, choledocholithiasis, prosthetic valves, contraindication to laparoscopy.</P>
<P>Trial duration: 25 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intravenous single cefotetan and cefazolin dose, 1 g each one given at the time of induction compared with placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Surgical site infection determined by pus drainage and extra-abdominal infections "any infection remote to the surgical site".</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Illig-1997">
<CHAR_METHODS>
<P>Randomised clinical trial with a parallel design.</P>
<P>Generation of the allocation sequence: unclear. </P>
<P>Allocation concealment: unclear.</P>
<P>Blinding: not performed. Outcome assessment was made by surgeons of the treatment group, but it was not stated whether they were blinded. </P>
<P>Follow-up: adequate. Lost to follow-up of 2.4% at 30 days.</P>
<P>Intention-to-treat analysis: yes.</P>
<P>Sample size calculations: yes. Power of 80%, alfa error of 5%, absolute difference to identify of 4%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-21 16:24:25 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>250 patients (128 for antibiotic group and 122 for no-antibiotic group).</P>
<P>Sex: 47 men/203 women.</P>
<P>Mean age: 46.5 to 47.3. Age of inclusion not reported.</P>
<P>Inclusion criteria: patients undergoing elective cholecystectomy.</P>
<P>Exclusions criteria: acute cholecystitis, obstructive jaundice, immunosuppression, pregnancy, artificial device or graft in place, use of antibiotics 7 days prior to surgery.</P>
<P>Trial duration: 25 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intravenous preoperative dose of cefazolin, 1 g given at the time of induction and followed by two doses at 8 and 16 hours postoperatively compared with no antibiotic in the control group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Surgical site infection determined by pus drainage and extra-abdominal infections "Lower urinary tract infection (UTIs, with symptomatic bacteriuria)...and any other problem with local effects only ...".</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-21 16:24:27 +0200" MODIFIED_BY="dimitrinka nikolova" STUDY_ID="STD-Koc-2003">
<CHAR_METHODS>
<P>Randomised clinical trial with a parallel design.</P>
<P>Generation of the allocation sequence: unclear. </P>
<P>Allocation concealment: unclear.</P>
<P>Blinding: yes. Use of placebo. Outcome assessment was made by surgeons of the treatment group, blinded to the interventions. </P>
<P>Follow-up: adequate. No losses to follow up.</P>
<P>Intention-to-treat analysis: no.</P>
<P>Sample size calculations: no.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-21 16:24:27 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>92 patients (49 for antibiotic group and 43 for no-antibiotic group).</P>
<P>Sex: 33 men/59 women.</P>
<P>Mean age: 47.5 to 50.1. Age of inclusion reported as adults.</P>
<P>Inclusion criteria: patients undergoing elective cholecystectomy.</P>
<P>Exclusions criteria: antibiotic allergy, acute cholecystitis, previous biliary surgery, obstructive jaundice, immunosuppression, artificial device or graft in place, use of antibiotics 7 days prior to surgery.</P>
<P>Trial duration: 12 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intravenous preoperative dose of cefotaxime, 2 g given at the time of induction and followed by a dose at 24 hours postoperatively compared with placebo in the control group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Surgical site infection determined by pus drainage.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Kuthe-2006">
<CHAR_METHODS>
<P>Randomised clinical trial with a parallel design.</P>
<P>Generation of the allocation sequence: Random number table. </P>
<P>Allocation concealment: unclear.</P>
<P>Blinding: yes. Use of placebo. Outcome assessment was made by residents of the treatment group, blinded to the interventions. </P>
<P>Follow-up: adequate. No losses to follow up.</P>
<P>Intention-to-treat analysis: No.</P>
<P>Sample size calculations: reported, but not clear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-21 16:24:29 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>93 patients (40 for antibiotic group and 53 for no-antibiotic group).</P>
<P>Sex: 25 men/68 women.</P>
<P>Mean age: 42.04 to 42.38. Age of inclusion reported as adults.</P>
<P>Inclusion criteria: patients undergoing elective cholecystectomy.</P>
<P>Exclusions criteria: antibiotic allergy, acute cholecystitis, previous biliary surgery, obstructive jaundice, immunosuppression, artificial device or graft in place, use of antibiotics 7 days prior to surgery, conversion to open surgery.</P>
<P>Trial duration: 12 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intravenous preoperative dose of cefotaxime, 1.5 g given at the time of induction compared with placebo in the control group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Surgical site infection determined by pus drainage and extra-abdominal infections (pyrexia of more than 38 C (excluding the first postoperative day), positive bacteriological culture from possible infection sites such as wounds, the urinary or respiratory tract..."</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-06 18:55:19 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Mahatharadol-2001">
<CHAR_METHODS MODIFIED="2010-08-06 18:55:19 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trial with a parallel design.</P>
<P>Generation of the allocation sequence: adequate.</P>
<P>Allocation concealment: unclear.</P>
<P>Blinding: no. Outcome assessment was made by surgeons of the treatment group, but it was not stated if they were blinded.</P>
<P>Follow-up: adequate. Lost to follow-up of 0.9%.</P>
<P>Intention-to-treat analysis: no. One patient who was lost to follow-up was excluded from the analysis.</P>
<P>Sample size calculations: no.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-04 05:14:54 +0200" MODIFIED_BY="[Empty name]">
<P>100 patients (50 for antibiotic group and 50 for no-antibiotic group).</P>
<P>Sex: 23 men/77 women.</P>
<P>Mean age: 51 to 52.2.</P>
<P>Age of inclusion: 15 to 80 years old.</P>
<P>Inclusion criteria: patients undergoing elective cholecystectomy.</P>
<P>Exclusions criteria: antibiotic allergy, acute cholecystitis, obstructive jaundice, immunosuppression, artificial device or graft in place, use of antibiotics 48 hours prior to surgery.</P>
<P>Duration of treatment: 7 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intravenous preoperative dose of cefazolin, 1 g given at the time of induction compared with no antibiotic in the control group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Surgical site infection determined by pus drainage.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-21 18:09:46 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharma-2010">
<CHAR_METHODS MODIFIED="2010-08-30 15:02:49 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial with a parallel design.</P>
<P>Generation of the allocation sequence: adequate.</P>
<P>Allocation concealment: adequate.</P>
<P>Blinding: yes. Use of placebo. Outcome assessment was made by residents of the treatment group, blinded to the interventions.</P>
<P>Follow-up: adequate. Lost to follow-up of 0%.</P>
<P>Intention-to-treat analysis: no. </P>
<P>Sample size calculations: no.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-21 18:09:46 +0200" MODIFIED_BY="[Empty name]">
<P>100 patients (50 for antibiotic group and 50 for no-antibiotic group).</P>
<P>Sex: 10 men/90 women.</P>
<P>Mean age: 39 to 39.</P>
<P>Age of inclusion: Older than 18 years old.</P>
<P>Inclusion criteria: patients undergoing elective cholecystectomy for symptomatic gallstone disease.</P>
<P>Exclusions criteria: jaundice, acute cholecystitis, cholangitis, acute pancreatitis or other acute inflammation, conversion to open cholecystectomy, immunosuppressive therapy, cardiac disorders mandating prophylactic use of antibiotics, or antibiotic use in the preceding seven days.</P>
<P>Duration of treatment: not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-30 15:06:40 +0200" MODIFIED_BY="[Empty name]">
<P>Intravenous preoperative dose of ceftriaxone, 1 g given at the time of induction compared with physiologic saline as placebo in the control group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-30 15:07:41 +0200" MODIFIED_BY="[Empty name]">
<P>"Superficial SSI was defined as erythema or purulent discharge at the surgical site above the deep fascia. A deep infection was defined as purulent material deep to the fascia or near the gallbladder fossa. A distant infection was defined as any infection remote from the surgical site."</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Tocchi-2000">
<CHAR_METHODS>
<P>Randomised clinical trial with a parallel design.</P>
<P>Generation of the allocation sequence: adequate. Computer randomisation. </P>
<P>Allocation concealment: unclear.</P>
<P>Blinding: yes. Use of placebo. Outcome assessment was made by surgeons of the treatment group who were blinded to the intervention. </P>
<P>Follow-up: adequate. No losses to follow up.</P>
<P>Intention-to-treat analysis: no. One patient who was lost to follow-up was excluded from the analysis.</P>
<P>Sample size calculations: no.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-21 16:24:31 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>84 patients (44 for antibiotic group and 40 for no-antibiotic group).</P>
<P>Sex: 33 men/51 women.</P>
<P>Mean age: 49.5 to 53.6. Age of inclusion not stated.</P>
<P>Inclusion criteria: patients undergoing elective cholecystectomy.</P>
<P>Exclusions criteria: antibiotic allergy, acute cholecystitis, obstructive jaundice or choledocholithiasis, previous ERCP, corticosteroid therapy, use of antibiotics 7 days prior to surgery, conversion to open surgery.</P>
<P>Trial duration: 2 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intravenous preoperative dose of cefotaxime, 2 g given at the time of induction and followed by a dose at 24 hours postoperatively compared with placebo in the control group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Surgical site infection determined by pus drainage and extra-abdominal infections "infectious complications were defined as pyrexia with a body temperature higher than 38<SUP>0</SUP> C twice a day (excluding the first postoperative day) and culture findings positive for pathogens from infectious sites such as wounds, the urinary or respiratory tract...".</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Uludag-2009">
<CHAR_METHODS MODIFIED="2010-05-05 18:12:11 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial with a parallel design.</P>
<P>Generation of the allocation sequence: adequate. Random selection.</P>
<P>Allocation concealment: Closed envelopes.</P>
<P>Blinding: No. Use of placebo. Outcome assessment was made by surgeons of the treatment group who were not blinded to the intervention.</P>
<P>Follow-up: adequate. No losses to follow up.</P>
<P>Intention-to-treat analysis: no. Patients converted to open cholecystectomy were excluded</P>
<P>Sample size calculations: no.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-06 18:56:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>144 patients (68 for antibiotic group and 76 for no-antibiotic group).</P>
<P>Sex: 22 men/122 women.</P>
<P>Mean age: 42.5 to 44.6. Age of inclusion not stated. Excluded patients older than 60 years</P>
<P>Inclusion criteria: patients undergoing elective cholecystectomy.</P>
<P>Exclusions criteria: patients older than 60 years; antibiotic intake in the 7 days prior to surgery; acute cholecystitis in the 6 months prior to the procedure; evidence of cholangitis and/or obstructive jaundice and biliary pancreatitis; regular corticosteroid therapy; pregnancy or lactation; previous biliary tract surgery or previous endoscopic retrograde cholangiopancreatography; presence of American Society of Anesthesiologists classification (ASA) higher than score II; evidence of diabetes mellitus; body mass index higher than 30; and conversion to open cholecystectomy.</P>
<P>Trial duration: 3 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-05 18:15:00 +0200" MODIFIED_BY="[Empty name]">
<P>Intravenous preoperative dose of cefazolin, 1 g given at the time of induction compared with placebo in the control group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-09 14:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Surgical site infection determined by pus drainage and extra-abdominal infections "number of septic complications".</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-21 18:10:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yildiz-2009">
<CHAR_METHODS MODIFIED="2010-05-05 17:03:03 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial with a parallel design.</P>
<P>Generation of the allocation sequence: adequate. Unclear.</P>
<P>Allocation concealment: unclear.</P>
<P>Blinding: yes. Use of placebo. Outcome assessment was made by surgeons of the treatment group who were blinded to the intervention.</P>
<P>Follow-up: adequate. No losses to follow up.</P>
<P>Intention-to-treat analysis: no. One patient who was lost to follow-up was excluded from the analysis.</P>
<P>Sample size calculations: no.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-21 18:09:56 +0200" MODIFIED_BY="[Empty name]">
<P>208 patients (105 for antibiotic group and 103 for no-antibiotic group).</P>
<P>Sex: 58 men/150 women.</P>
<P>Mean age: 49.9 to 51.3. Age of inclusion not stated.</P>
<P>Inclusion criteria: patients undergoing elective cholecystectomy.</P>
<P>Exclusions criteria: conversion to laparotomy, acute cholecystitis, evidence of obstructive jaundice, history of biliary tract surgery, prosthetic valves, chronic hepatic diseases, acute pancreatitis, immunosuppression, steroid therapy, chronic systemic infections, allergy to &#946;-lactam antibiotics.</P>
<P>Trial duration: 3 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-05 17:07:26 +0200" MODIFIED_BY="[Empty name]">
<P>Intravenous preoperative dose of cefazolin, 1 g given at the time of induction compared with placebo in the control group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-21 18:10:06 +0200" MODIFIED_BY="[Empty name]">
<P>Surgical site infection determined by body temperature higher than 38°C, purulent discharge from the incisions, and any abdominal signs of infection.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-09-21 18:10:13 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Anselmi-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Quasi-randomised trial. Randomisation was performed after date of birth.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 18:10:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chang-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 18:10:08 +0200" MODIFIED_BY="[Empty name]">
<P>Included patients with acute cholecystitis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gonzales-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Published as a theses. We could not obtain copy of the thesis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-21 18:10:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Uchiyama-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-21 18:10:13 +0200" MODIFIED_BY="[Empty name]">
<P>Comparative, not randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-11-09 15:04:23 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-09-21 18:08:43 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-21 18:08:43 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Csendes-1995">
<DESCRIPTION>
<P>Unclear. "Randomly distributed into two groups", "Se dividieron en dos grupos al azar".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-10 12:53:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harling-2000">
<DESCRIPTION>
<P>Unclear."Patients ... were randomised to receive...".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-21 16:10:25 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Higgins-1999">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-10 12:53:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Illig-1997">
<DESCRIPTION>
<P>Patients were randomised to receive prophylactic antibiotics.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-10 12:53:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koc-2003">
<DESCRIPTION>
<P>After the patients were confirmed for the study, they were randomised....</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-21 16:12:23 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Kuthe-2006">
<DESCRIPTION>
<P>Random number table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-10 12:53:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mahatharadol-2001">
<DESCRIPTION>
<P>By block randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-30 15:08:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sharma-2010">
<DESCRIPTION>
<P>"Anesthetist randomly opened one of a collection of sealed envelopes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-19 05:58:56 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tocchi-2000">
<DESCRIPTION>
<P>Compute-matrix randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-16 20:08:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Uludag-2009">
<DESCRIPTION>
<P>Random selection "One of 2 packages containing either cefazolin or placebo was chosen randomly by the anaesthesiologist for each patient."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 18:56:30 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Yildiz-2009">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-10-08 18:09:34 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-08 18:09:34 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Csendes-1995">
<DESCRIPTION>
<P>Unclear. "Randomly distributed into two groups", "Se dividieron en dos grupos al azar".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 18:57:01 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Harling-2000">
<DESCRIPTION>
<P>"Randomisation ... was done using a sealed envelope technique".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-21 16:10:01 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Higgins-1999">
<DESCRIPTION>
<P>Sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-10 12:53:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Illig-1997">
<DESCRIPTION>
<P>Patients were randomised to receive prophylactic antibiotics.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-10 12:53:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koc-2003">
<DESCRIPTION>
<P>After the patients were confirmed for the study, they were randomised... .</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-21 16:12:08 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Kuthe-2006">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-10 12:53:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mahatharadol-2001">
<DESCRIPTION>
<P>By block randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-30 15:09:43 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-2010">
<DESCRIPTION>
<P>"Anesthetist randomly opened one of a collection of sealed envelopes", "The surgeon and medical staff were unaware of which treatment the patient received."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-19 05:59:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tocchi-2000">
<DESCRIPTION>
<P>Compute-matrix randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-16 20:08:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Uludag-2009">
<DESCRIPTION>
<P>Closed envelope method "The package was opened by the anaesthesiologist, and the type of solution administered (cefazolin or placebo) was recorded. The medical staff and the patient were unaware of the content of the solution."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 18:56:31 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Yildiz-2009">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-09-21 18:09:17 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-21 18:09:17 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Csendes-1995">
<DESCRIPTION>
<P>"Patients were controlled during hospital stay and then, 15 days after discharge in an out-patient setting, recording data about infection", "Los pacientes fueron controlados en su estadia intrahospitalaria y luego hasta 15 dias en forma ambulatoria consignando la presencia de cualquier infeccion"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-06 18:53:49 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Harling-2000">
<DESCRIPTION>
<P>"An infection control sister followed up the patients".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-21 16:10:18 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Higgins-1999">
<DESCRIPTION>
<P>Outcome assessment was made by surgeons of the treatment group blind to intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-06 18:54:18 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Illig-1997">
<DESCRIPTION>
<P>Complications were reported to the investigators as they occurred.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-06 18:54:45 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Koc-2003">
<DESCRIPTION>
<P>Both the surgical team and the patients were blinded to the groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-04-19 05:56:01 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuthe-2006">
<DESCRIPTION>
<P>Outcome assessment was made by residents of the treatment group, blinded to the interventions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-06 18:55:32 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Mahatharadol-2001">
<DESCRIPTION>
<P>All patients were followed-up for 30 days after the procedure at the out-patient clinic or by telephone contact.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-30 15:09:56 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-2010">
<DESCRIPTION>
<P>"The surgeon and medical staff were unaware of which treatment the patient received."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-06 18:55:49 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Tocchi-2000">
<DESCRIPTION>
<P>Patients were followed postoperatively.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-06 18:56:09 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Uludag-2009">
<DESCRIPTION>
<P>Patients were followed postoperatively by the same surgical group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-05 17:09:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yildiz-2009">
<DESCRIPTION>
<P>"The patients were followed up regularly until the day of discharge and on 7th and 30th days postoperatively by the same surgical team (Dr. OA and Dr. EH) who were blind to AP."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-08-30 15:10:48 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-08-06 18:53:36 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Csendes-1995">
<DESCRIPTION>
<P>Per protocol analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-08-06 18:53:49 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Harling-2000">
<DESCRIPTION>
<P>Per protocol analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-08-06 18:54:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Higgins-1999">
<DESCRIPTION>
<P>Per protocol analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-08-06 18:54:19 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Illig-1997">
<DESCRIPTION>
<P>Intention to treat analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-08-06 18:54:48 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Koc-2003">
<DESCRIPTION>
<P>Per protocol analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-08-06 18:55:12 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Kuthe-2006">
<DESCRIPTION>
<P>Per protocol analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-08-06 18:55:33 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Mahatharadol-2001">
<DESCRIPTION>
<P>Per protocol analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-08-30 15:10:48 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sharma-2010">
<DESCRIPTION>
<P>Per protocol analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-08-06 18:55:49 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Tocchi-2000">
<DESCRIPTION>
<P>Per protocol analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-08-06 18:56:10 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Uludag-2009">
<DESCRIPTION>
<P>Per protocol analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-08-06 18:56:33 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Yildiz-2009">
<DESCRIPTION>
<P>Per protocol analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2010-11-09 15:04:23 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="9">
<NAME>Vested interest bias</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-21 18:09:09 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Csendes-1995">
<DESCRIPTION>
<P>It is not possible to say if there were or there were not any financial interests. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:02:36 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Harling-2000">
<DESCRIPTION>
<P>It is not possible to say if there were or there were not financial interests.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:02:51 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Higgins-1999">
<DESCRIPTION>
<P>It is not possible to say if there were or there were not financial interests. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:03:19 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Illig-1997">
<DESCRIPTION>
<P>It is not possible to say if there were or there were not financial interests.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:03:31 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Koc-2003">
<DESCRIPTION>
<P>It is not possible to say if there were or there were not financial interests.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:03:40 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Kuthe-2006">
<DESCRIPTION>
<P>It is not possible to say that there were or there were not financial interests.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:03:50 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Mahatharadol-2001">
<DESCRIPTION>
<P>It is not possible to say if there were or there were not financial interests.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:03:58 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Sharma-2010">
<DESCRIPTION>
<P>It is not possible to say if there were or there were not financial interests.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:04:05 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Tocchi-2000">
<DESCRIPTION>
<P>It is not possible to say if there were or there were not financial interests.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:04:15 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Uludag-2009">
<DESCRIPTION>
<P>It is not possible to say if there were or there were not financial interests.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:04:23 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Yildiz-2009">
<DESCRIPTION>
<P>It is not possible to say if there were or there were not financial interests.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-10-21 16:18:47 +0200" MODIFIED_BY="dimitrinka nikolova"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-11-10 21:40:43 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-11-10 21:40:43 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Antibiotic prophylaxis versus placebo or no-prophylaxis</NAME>
<DICH_OUTCOME CHI2="2.403862071032036" CI_END="1.5385868657373138" CI_START="0.49437951394591884" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8721501171511633" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.1871220207299911" LOG_CI_START="-0.30593953380228467" LOG_EFFECT_SIZE="-0.0594087565361468" METHOD="MH" MODIFIED="2010-10-08 18:44:32 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.9922038530261461" P_Q="0.0" P_Z="0.6367053274393295" Q="0.0" RANDOM="NO" SCALE="126.60470650076581" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="900" TOTAL_2="764" WEIGHT="100.0" Z="0.4723102911059928">
<NAME>Surgical site infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.403862071032036" CI_END="1.5385868657373138" CI_START="0.49437951394591884" DF="10" EFFECT_SIZE="0.8721501171511633" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.1871220207299911" LOG_CI_START="-0.30593953380228467" LOG_EFFECT_SIZE="-0.0594087565361468" MODIFIED="2010-09-09 16:19:57 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9922038530261461" P_Z="0.6367053274393295" STUDIES="11" TAU2="0.0" TOTAL_1="900" TOTAL_2="764" WEIGHT="100.0" Z="0.4723102911059928">
<NAME>Per protocol analysis (Intention-to-treat analysis not performed)</NAME>
<DICH_DATA CI_END="8.146453881237878" CI_START="0.149658249534277" EFFECT_SIZE="1.1041666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9109686032242866" LOG_CI_START="-0.824899338773883" LOG_EFFECT_SIZE="0.04303463222520185" ORDER="1" O_E="0.0" SE="1.0196574218146188" STUDY_ID="STD-Csendes-1995" TOTAL_1="50" TOTAL_2="55" VAR="1.0397012578616354" WEIGHT="7.167724097927932"/>
<DICH_DATA CI_END="5.004681831352395" CI_START="0.17822817487699125" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6993764727683479" LOG_CI_START="-0.7490236402184122" LOG_EFFECT_SIZE="-0.024823583725032152" ORDER="4" O_E="0.0" SE="0.8507973960646135" STUDY_ID="STD-Harling-2000" TOTAL_1="39" TOTAL_2="37" VAR="0.7238562091503268" WEIGHT="11.140623803522855"/>
<DICH_DATA CI_END="6.3835370690527204" CI_START="0.23409067102300998" EFFECT_SIZE="1.2224264705882353" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.8050613846638364" LOG_CI_START="-0.6306158934539869" LOG_EFFECT_SIZE="0.08722274560492468" ORDER="3" O_E="0.0" SE="0.8433239398835518" STUDY_ID="STD-Higgins-1999" TOTAL_1="277" TOTAL_2="135" VAR="0.7111952675807165" WEIGHT="10.351446209386213"/>
<DICH_DATA CI_END="7.811334570085696" CI_START="0.012716820800829311" EFFECT_SIZE="0.3151750972762646" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8927252396274865" LOG_CI_START="-1.895621448532776" LOG_EFFECT_SIZE="-0.5014481044526448" ORDER="2" O_E="0.0" SE="1.637888647164049" STUDY_ID="STD-Illig-1997" TOTAL_1="128" TOTAL_2="122" VAR="2.682679220508879" WEIGHT="5.996435850154552"/>
<DICH_DATA CI_END="14.426126157479537" CI_START="0.05307211316761187" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1591497258061922" LOG_CI_START="-1.275133619761566" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="7" O_E="0.0" SE="1.4299100870834" STUDY_ID="STD-Koc-2003" TOTAL_1="49" TOTAL_2="43" VAR="2.0446428571428568" WEIGHT="4.090277338491483"/>
<DICH_DATA CI_END="7.474592557209754" CI_START="0.057195732025157826" EFFECT_SIZE="0.6538461538461539" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.8735875240896824" LOG_CI_START="-1.2426363772747706" LOG_EFFECT_SIZE="-0.18452442659254403" ORDER="8" O_E="0.0" SE="1.2430803951387377" STUDY_ID="STD-Kuthe-2006" TOTAL_1="40" TOTAL_2="53" VAR="1.5452488687782804" WEIGHT="6.575230775316954"/>
<DICH_DATA CI_END="8.2145947674557" CI_START="0.012995679373418273" EFFECT_SIZE="0.32673267326732675" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9145861442045954" LOG_CI_START="-1.8862010120141053" LOG_EFFECT_SIZE="-0.48580743390475506" MODIFIED="2010-09-09 16:19:57 +0200" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="1.6451962396828856" STUDY_ID="STD-Mahatharadol-2001" TOTAL_1="50" TOTAL_2="50" VAR="2.7066706670667067" WEIGHT="5.822128834139531"/>
<DICH_DATA CI_END="2.743354125497899" CI_START="0.0836934219721902" EFFECT_SIZE="0.4791666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4382818720678631" LOG_CI_START="-1.0773086747838518" LOG_EFFECT_SIZE="-0.31951340135799433" MODIFIED="2010-08-30 15:13:14 +0200" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.8902653895148996" STUDY_ID="STD-Sharma-2010" TOTAL_1="50" TOTAL_2="50" VAR="0.792572463768116" WEIGHT="15.052220605648657"/>
<DICH_DATA CI_END="3.1415475535970274" CI_START="0.138043568294477" EFFECT_SIZE="0.6585365853658537" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.49714363801613953" LOG_CI_START="-0.8599838231376358" LOG_EFFECT_SIZE="-0.18142009256074818" ORDER="5" O_E="0.0" SE="0.7971833885710051" STUDY_ID="STD-Tocchi-2000" TOTAL_1="44" TOTAL_2="40" VAR="0.6355013550135501" WEIGHT="15.306077500783605"/>
<DICH_DATA CI_END="10.539133286340565" CI_START="0.27670330552998035" EFFECT_SIZE="1.7076923076923076" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.0228048969830976" LOG_CI_START="-0.5579856526954938" LOG_EFFECT_SIZE="0.23240962214380184" MODIFIED="2010-05-05 18:02:56 +0200" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.9285641939206262" STUDY_ID="STD-Uludag-2009" TOTAL_1="68" TOTAL_2="76" VAR="0.8622314622314622" WEIGHT="7.077505348431443"/>
<DICH_DATA CI_END="6.049645799579224" CI_START="0.28807447411221754" EFFECT_SIZE="1.3201320132013201" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.781729947910096" LOG_CI_START="-0.5404952222587811" LOG_EFFECT_SIZE="0.12061736282565738" MODIFIED="2010-05-05 17:18:39 +0200" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="0.776681610077349" STUDY_ID="STD-Yildiz-2009" TOTAL_1="105" TOTAL_2="103" VAR="0.6032343234323432" WEIGHT="11.420329636196772"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9974399336591739" CI_END="1.7430140066954076" CI_START="0.25176029324853266" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6624361987859175" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.24130087707332296" LOG_CI_START="-0.5990127642315323" LOG_EFFECT_SIZE="-0.17885594357910464" METHOD="MH" MODIFIED="2010-11-10 21:40:43 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8018714321866156" P_Q="0.0" P_Z="0.4040926889866491" Q="0.0" RANDOM="NO" SCALE="46.444823954952135" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="657" TOTAL_2="531" WEIGHT="100.0" Z="0.8343342071458709">
<NAME>Extra-abdominal infections</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Csendes-1995" TOTAL_1="50" TOTAL_2="55" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="36.32744013041528" CI_START="0.05949713218824236" EFFECT_SIZE="1.4701627486437614" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5602347957046012" LOG_CI_START="-1.2255039671258616" LOG_EFFECT_SIZE="0.16736541428936993" MODIFIED="2010-11-10 21:09:19 +0100" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="1.6363567389158862" STUDY_ID="STD-Higgins-1999" TOTAL_1="277" TOTAL_2="135" VAR="2.6776633769954334" WEIGHT="6.5376948861343305"/>
<DICH_DATA CI_END="5.27799775865633" CI_START="0.04228884827296992" EFFECT_SIZE="0.47244094488188976" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7224692014574688" LOG_CI_START="-1.373774142602095" LOG_EFFECT_SIZE="-0.3256524705723132" MODIFIED="2010-11-10 21:32:47 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="1.2313437168724923" STUDY_ID="STD-Illig-1997" TOTAL_1="128" TOTAL_2="122" VAR="1.5162073490813648" WEIGHT="19.890859846548764"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-11-10 21:34:38 +0100" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuthe-2006" TOTAL_1="40" TOTAL_2="53" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-30 15:14:01 +0200" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.0" STUDY_ID="STD-Sharma-2010" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.876449039950656" CI_START="0.028600086273419575" EFFECT_SIZE="0.2868217054263566" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45885668433604543" LOG_CI_START="-1.5436326568005534" LOG_EFFECT_SIZE="-0.5423879862322539" MODIFIED="2010-11-10 21:39:27 +0100" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="1.1762721514657433" STUDY_ID="STD-Tocchi-2000" TOTAL_1="44" TOTAL_2="40" VAR="1.3836161743138486" WEIGHT="30.065627580202367"/>
<DICH_DATA CI_END="3.4492098090812564" CI_START="0.2283584628358119" EFFECT_SIZE="0.8875" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.5377196125044996" LOG_CI_START="-0.6413828890502362" LOG_EFFECT_SIZE="-0.051831638272868324" MODIFIED="2010-11-10 21:40:43 +0100" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="0.6926106460647667" STUDY_ID="STD-Uludag-2009" TOTAL_1="68" TOTAL_2="76" VAR="0.4797095070422535" WEIGHT="43.505817687114536"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.063810818686523" CI_END="4.463921570373506" CI_START="1.751107119248064" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="OR" EFFECT_SIZE="2.795854939306767" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="25" I2="23.45265758368176" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.6497165555860573" LOG_CI_START="0.2433127136879027" LOG_EFFECT_SIZE="0.44651463463698005" METHOD="MH" MODIFIED="2010-11-09 15:01:07 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="3" P_CHI2="0.22012605642677052" P_Q="0.0" P_Z="1.6562377750888033E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="952" TOTAL_2="804" WEIGHT="99.99999999999999" Z="4.306812644147476">
<NAME>Surgical site infection (Intention-to-treat analysis worst-best case scenario)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.146453881237878" CI_START="0.149658249534277" EFFECT_SIZE="1.1041666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9109686032242866" LOG_CI_START="-0.824899338773883" LOG_EFFECT_SIZE="0.04303463222520185" MODIFIED="2010-11-08 17:31:13 +0100" MODIFIED_BY="Dimitrinka Nikolova" ORDER="147" O_E="0.0" SE="1.0196574218146188" STUDY_ID="STD-Csendes-1995" TOTAL_1="50" TOTAL_2="55" VAR="1.0397012578616354" WEIGHT="7.696796429783511"/>
<DICH_DATA CI_END="11.449168257660194" CI_START="0.6920312692932841" EFFECT_SIZE="2.814814814814815" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.05877393783495" LOG_CI_START="-0.15987428159134184" LOG_EFFECT_SIZE="0.44944982812180406" MODIFIED="2010-09-09 16:30:40 +0200" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="0.7158399964969793" STUDY_ID="STD-Harling-2000" TOTAL_1="44" TOTAL_2="41" VAR="0.5124269005847953" WEIGHT="10.69628327374326"/>
<DICH_DATA CI_END="33.65207286404322" CI_START="1.8634126221174991" EFFECT_SIZE="7.918819188191882" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="2" LOG_CI_END="1.5270118205864245" LOG_CI_START="0.2703090329246284" LOG_EFFECT_SIZE="0.8986604267555265" MODIFIED="2010-08-23 15:44:17 +0200" MODIFIED_BY="[Empty name]" ORDER="53" O_E="0.0" SE="0.7381934382516655" STUDY_ID="STD-Higgins-1999" TOTAL_1="300" TOTAL_2="150" VAR="0.5449295522778155" WEIGHT="10.139460296735638"/>
<DICH_DATA CI_END="7.811334570085696" CI_START="0.012716820800829311" EFFECT_SIZE="0.3151750972762646" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8927252396274865" LOG_CI_START="-1.895621448532776" LOG_EFFECT_SIZE="-0.5014481044526448" MODIFIED="2010-08-23 15:40:59 +0200" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="1.637888647164049" STUDY_ID="STD-Illig-1997" TOTAL_1="128" TOTAL_2="122" VAR="2.682679220508879" WEIGHT="6.439051700697793"/>
<DICH_DATA CI_END="95.80407863774056" CI_START="1.4822640796057192" EFFECT_SIZE="11.916666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.9813839985582806" LOG_CI_START="0.17092558427659335" LOG_EFFECT_SIZE="1.076154791417437" MODIFIED="2010-09-09 16:32:41 +0200" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="1.0634722344627496" STUDY_ID="STD-Koc-2003" TOTAL_1="59" TOTAL_2="53" VAR="1.1309731934731935" WEIGHT="3.6078733264610205"/>
<DICH_DATA CI_END="25.490754649406178" CI_START="0.9908324828348917" EFFECT_SIZE="5.0256410256410255" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.4063826928730134" LOG_CI_START="-0.0039997642130596795" LOG_EFFECT_SIZE="0.7011914643299768" MODIFIED="2010-09-09 16:35:16 +0200" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.8284656367981181" STUDY_ID="STD-Kuthe-2006" TOTAL_1="46" TOTAL_2="58" VAR="0.6863553113553114" WEIGHT="6.313778321306787"/>
<DICH_DATA CI_END="23.241129454397452" CI_START="0.17920520114162772" EFFECT_SIZE="2.0408163265306123" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3662572297377995" LOG_CI_START="-0.7466493897948266" LOG_EFFECT_SIZE="0.3098039199714864" MODIFIED="2010-08-23 15:41:14 +0200" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="1.2411318073699127" STUDY_ID="STD-Mahatharadol-2001" TOTAL_1="51" TOTAL_2="51" VAR="1.5404081632653062" WEIGHT="4.0441194476344124"/>
<DICH_DATA CI_END="2.743354125497899" CI_START="0.0836934219721902" EFFECT_SIZE="0.4791666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4382818720678631" LOG_CI_START="-1.0773086747838518" LOG_EFFECT_SIZE="-0.31951340135799433" MODIFIED="2010-11-08 17:31:39 +0100" MODIFIED_BY="Dimitrinka Nikolova" ORDER="148" O_E="0.0" SE="0.8902653895148996" STUDY_ID="STD-Sharma-2010" TOTAL_1="50" TOTAL_2="50" VAR="0.792572463768116" WEIGHT="16.16327250254537"/>
<DICH_DATA CI_END="5.44343252773071" CI_START="0.3739996317553965" EFFECT_SIZE="1.4268292682926829" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7358728441358483" LOG_CI_START="-0.42712882541095837" LOG_EFFECT_SIZE="0.15437200936244494" MODIFIED="2010-09-09 16:37:30 +0200" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.6831529376429054" STUDY_ID="STD-Tocchi-2000" TOTAL_1="47" TOTAL_2="43" VAR="0.46669793621013134" WEIGHT="15.34014288436019"/>
<DICH_DATA CI_END="20.390794449148167" CI_START="0.8213011165545991" EFFECT_SIZE="4.092307692307692" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.3094341467276167" LOG_CI_START="-0.08549758675119375" LOG_EFFECT_SIZE="0.6119682799882113" MODIFIED="2010-08-23 15:41:26 +0200" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.8193898052688967" STUDY_ID="STD-Uludag-2009" TOTAL_1="72" TOTAL_2="78" VAR="0.6713996529786004" WEIGHT="7.295921615732286"/>
<DICH_DATA CI_END="6.049645799579224" CI_START="0.28807447411221754" EFFECT_SIZE="1.3201320132013201" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.781729947910096" LOG_CI_START="-0.5404952222587811" LOG_EFFECT_SIZE="0.12061736282565738" MODIFIED="2010-11-08 17:31:55 +0100" MODIFIED_BY="Dimitrinka Nikolova" ORDER="149" O_E="0.0" SE="0.776681610077349" STUDY_ID="STD-Yildiz-2009" TOTAL_1="105" TOTAL_2="103" VAR="0.6032343234323432" WEIGHT="12.26330020099972"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.130314765496726" CI_END="0.544287236157628" CI_START="0.21191957838282083" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="OR" EFFECT_SIZE="0.33962497199952085" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="61" I2="1.2863841698243226" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.26417185001382076" LOG_CI_START="-0.6738289187453503" LOG_EFFECT_SIZE="-0.46900038437958563" METHOD="MH" MODIFIED="2010-11-09 15:01:14 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="4" P_CHI2="0.4291358358100308" P_Q="0.0" P_Z="7.197172645505266E-6" Q="0.0" RANDOM="NO" SCALE="239.94341941166826" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="952" TOTAL_2="804" WEIGHT="100.0" Z="4.487772492078474">
<NAME>Surgical site infection (Intention-to-treat analysis best-worst case scenario)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.146453881237878" CI_START="0.149658249534277" EFFECT_SIZE="1.1041666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9109686032242866" LOG_CI_START="-0.824899338773883" LOG_EFFECT_SIZE="0.04303463222520185" MODIFIED="2010-11-08 17:08:03 +0100" MODIFIED_BY="Dimitrinka Nikolova" ORDER="150" O_E="0.0" SE="1.0196574218146188" STUDY_ID="STD-Csendes-1995" TOTAL_1="50" TOTAL_2="55" VAR="1.0397012578616354" WEIGHT="2.8640811518458897"/>
<DICH_DATA CI_END="1.4804643667173547" CI_START="0.08531759235216409" EFFECT_SIZE="0.3554006968641115" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.17039795882139272" LOG_CI_START="-1.0689614087655424" LOG_EFFECT_SIZE="-0.44928172497207475" MODIFIED="2010-09-09 16:31:00 +0200" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.728005827448378" STUDY_ID="STD-Harling-2000" TOTAL_1="44" TOTAL_2="41" VAR="0.5299924847987976" WEIGHT="10.57709381260734"/>
<DICH_DATA CI_END="0.5109991952301158" CI_START="0.062435298190807786" EFFECT_SIZE="0.17861799217731422" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="-0.29157978383279237" LOG_CI_START="-1.2045698097523558" LOG_EFFECT_SIZE="-0.7480747967925742" MODIFIED="2010-08-23 15:43:35 +0200" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.5362948605986675" STUDY_ID="STD-Higgins-1999" TOTAL_1="300" TOTAL_2="150" VAR="0.2876121775045442" WEIGHT="26.696617542119064"/>
<DICH_DATA CI_END="7.811334570085696" CI_START="0.012716820800829311" EFFECT_SIZE="0.3151750972762646" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8927252396274865" LOG_CI_START="-1.895621448532776" LOG_EFFECT_SIZE="-0.5014481044526448" MODIFIED="2010-08-23 15:42:39 +0200" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="1.637888647164049" STUDY_ID="STD-Illig-1997" TOTAL_1="128" TOTAL_2="122" VAR="2.682679220508879" WEIGHT="2.3960574740377396"/>
<DICH_DATA CI_END="0.529727658903068" CI_START="0.008180965737689687" EFFECT_SIZE="0.06583072100313479" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.2759473504637307" LOG_CI_START="-2.0871954261827934" LOG_EFFECT_SIZE="-1.181571388323262" MODIFIED="2010-09-09 16:33:04 +0200" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="1.0639360854999511" STUDY_ID="STD-Koc-2003" TOTAL_1="59" TOTAL_2="53" VAR="1.1319599940289593" WEIGHT="17.84456811403982"/>
<DICH_DATA CI_END="1.3668969969988534" CI_START="0.01917712306413065" EFFECT_SIZE="0.1619047619047619" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.13573578938827988" LOG_CI_START="-1.7172165447716083" LOG_EFFECT_SIZE="-0.7907403776916642" MODIFIED="2010-09-09 16:35:28 +0200" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="1.0884333733475007" STUDY_ID="STD-Kuthe-2006" TOTAL_1="46" TOTAL_2="58" VAR="1.1846872082166198" WEIGHT="9.488129416797156"/>
<DICH_DATA CI_END="5.580195182000827" CI_START="0.0430271687941048" EFFECT_SIZE="0.49" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7466493897948266" LOG_CI_START="-1.3662572297377995" LOG_EFFECT_SIZE="-0.3098039199714863" MODIFIED="2010-08-23 15:42:47 +0200" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="1.2411318073699127" STUDY_ID="STD-Mahatharadol-2001" TOTAL_1="51" TOTAL_2="51" VAR="1.5404081632653062" WEIGHT="3.071165450815139"/>
<DICH_DATA CI_END="2.743354125497899" CI_START="0.0836934219721902" EFFECT_SIZE="0.4791666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4382818720678631" LOG_CI_START="-1.0773086747838518" LOG_EFFECT_SIZE="-0.31951340135799433" MODIFIED="2010-11-08 17:08:21 +0100" MODIFIED_BY="Dimitrinka Nikolova" ORDER="151" O_E="0.0" SE="0.8902653895148996" STUDY_ID="STD-Sharma-2010" TOTAL_1="50" TOTAL_2="50" VAR="0.792572463768116" WEIGHT="6.014570418876368"/>
<DICH_DATA CI_END="1.454193755475314" CI_START="0.08455198397590595" EFFECT_SIZE="0.35064935064935066" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.1626222753866279" LOG_CI_START="-1.0728761974136172" LOG_EFFECT_SIZE="-0.45512696101349454" MODIFIED="2010-09-09 16:37:48 +0200" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.7257379187389389" STUDY_ID="STD-Tocchi-2000" TOTAL_1="47" TOTAL_2="43" VAR="0.5266955266955267" WEIGHT="10.720414866978711"/>
<DICH_DATA CI_END="3.723772435357439" CI_START="0.17374193417077347" EFFECT_SIZE="0.8043478260869565" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5709831328119106" LOG_CI_START="-0.7600953480410687" LOG_EFFECT_SIZE="-0.09455610761457907" MODIFIED="2010-08-23 15:43:05 +0200" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.7818820885977854" STUDY_ID="STD-Uludag-2009" TOTAL_1="72" TOTAL_2="78" VAR="0.6113396004700352" WEIGHT="5.7639633180898535"/>
<DICH_DATA CI_END="6.049645799579224" CI_START="0.28807447411221754" EFFECT_SIZE="1.3201320132013201" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.781729947910096" LOG_CI_START="-0.5404952222587811" LOG_EFFECT_SIZE="0.12061736282565738" MODIFIED="2010-11-08 17:08:42 +0100" MODIFIED_BY="Dimitrinka Nikolova" ORDER="152" O_E="0.0" SE="0.776681610077349" STUDY_ID="STD-Yildiz-2009" TOTAL_1="105" TOTAL_2="103" VAR="0.6032343234323432" WEIGHT="4.563338433792918"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-11-10 21:40:44 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-10-08 18:44:33 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Antibiotic prophylaxis versus no-prophylaxis, outcome: 1.1 Surgical site infection.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-11-10 21:40:44 +0100" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.02" SETTINGS="SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Antibiotic prophylaxis versus no-prophylaxis, outcome: 1.2 Global infections.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-11-09 15:04:24 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2010-11-09 15:04:24 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-11-03 14:57:33 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-11-03 14:57:33 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-10-21 16:18:31 +0200" MODIFIED_BY="dimitrinka nikolova">Search Strategies</TITLE>
<APPENDIX_BODY MODIFIED="2010-11-03 14:57:33 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="7">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Database</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Period</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search strategy</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Hepato-Biliary Group Controlled Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>August 2010</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>((antibiotic* OR prophyla*) AND (laparoscop* AND cholecystectom*)) AND #20 &gt;=1985</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Central Register of Controlled Trials in The Cochrane Library</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 3, 2010</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 MeSH descriptor Antibiotic Prophylaxis explode all trees<BR/>#2 antibiotic* OR prophyla*<BR/>#3 (#1 OR #2)<BR/>#4 MeSH descriptor Laparoscopy explode all trees<BR/>#5 laparoscop* AND cholecystectom*<BR/>#6 (#4 OR #5)<BR/>#7 (#3 AND #6), from 1985 to 2010</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE (Ovid SP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1985 to August 2010</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. exp Antibiotic Prophylaxis/<BR/>2. (antibiotic* or prophyla*).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]<BR/>3. 1 or 2<BR/>4. exp Laparoscopy/<BR/>5. (laparoscop* and cholecystectom*).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]<BR/>6. 4 or 5<BR/>7. 3 and 6<BR/>8. (random* or blind* or placebo* or meta-analysis).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]<BR/>9. 7 and 8<BR/>10. limit 9 to yr="1985 -Current"</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EMBASE (Ovid SP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1985 to August 2010</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. exp antibiotic prophylaxis/<BR/>2. (antibiotic* or prophyla*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer]<BR/>3. 1 or 2<BR/>4. exp LAPAROSCOPY/<BR/>5. (laparoscop* and cholecystectom*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer]<BR/>6. 4 or 5<BR/>7. 3 and 6<BR/>8. (random* or blind* or placebo* or meta-analysis).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer]<BR/>9. 7 and 8<BR/>10. limit 9 to yr="1985 -Current"</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>LILACS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1985 to August 2010</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 "COLECISTECTOMIA"<BR/>#2 "LAPAROSCOPIA"<BR/>#3 "ANTIBIOTICOS"<BR/>#4 "PROFILAXIS"<BR/>#5 #1 OR #2<BR/>#6 #3 OR #4<BR/>#7 #5 AND #6</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Science Citation Index Expanded (http://apps.isiknowledge.com)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1985 to August 2010</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 5 #4 AND #3<BR/># 4 TS=(random* or blind* or placebo* or meta-analysis)<BR/># 3 #2 AND #1<BR/># 2 TS=(laparoscop* and cholecystectom*)<BR/># 1 TS=(antibiotic* or prophyla*)</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>